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ABSTRACT

Multiple drug resistance (MDR) in tumors, observed both in vivo and in vitro, is
generally attributed to efflux-mediated reduced drug accumulation via mdr1/P-gp.
Notoriously chemoresistant colorectal cancers exhibit the highest P-gp expression,
account for 9% of all cancer deaths, and are the third most common cancer in men and
women. P-gp, a 170kDa protein, contains twelve transmembrane segments with two
ATP-binding domains used to extrude intracellular compounds of broad specificity
against a concentration gradient. Studies concerning natural health products are
becoming more prevalent in the search for safe anti-P-gp remedies and Hydrastis
canadensis (goldenseal) was studied for its anti-cancer properties. Three forms of
goldenseal from Sleepy Hollow Herb Farm (Dalton, Georgia) were tested in the Ames
mutagenicity assay. The liquid extract, powder, and solid were tested in five ratios of
root/rhizome:leaf/stem at five concentrations based on the minimum inhibitory
concentrations to the tester Salmonella strain and compared to equivalent berberine
amounts. All forms, ratios, and concentrations of goldenseal and berberine equivalents
were found to be non-mutagenic. Goldenseal liquid in equal parts of root:leaf (GSL2:2)
exerted the greatest activity with lowest toxicity and was assayed for its in vitro effects
on colon cell viability, mdr1 gene expression, P-gp function, and ability to potentiate a
chemotherapeutic drug. At 400µg/mL GSL2:2, HT-29 and doxorubicin-treated HT-29
(HT-29/Dox) but not CCD-18Co were significantly inhibited after 72 hours. Increasing
amounts of GSL2:2 caused over 90% of cell death in CCD-18Co and HT-29; HT-29/Dox
were still 50% viable even when treated with 6400µg/mL GSL2:2 after 72h. GSL2:2 at
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400µg/mL led to significant increases in mdr1 gene expression in CCD-18Co after 24,
48, and 72 hours but did not significantly alter levels in HT-29 or HT-29/Dox. GSL2:2 at
100µg/mL and 400µg/mL reduced P-gp function in HT-29 and in HT-29/Dox at
400µg/mL. GSL2:2 potentiated the action of vinblastine in HT-29 and HT-29/Dox,
though not in CCD-18Co. GSL2:2 was found to be non-mutagenic, possess anti-tumor
properties, decrease P-gp function in colon cancer cells and potentiate a drug. Therefore
it is plausible that GSL2:2 could be co-administered with a chemotherapeutic to cancer
patients to overcome MDR and achieve treatment success.
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CHAPTER ONE
LITERATURE REVIEW

1.1 Overview of Carcinogenesis

Cells within the human body perform highly regulated functions, including
interacting with food-borne mutagens, xenotoxins, over-the counter drugs, and
prescriptions that are consumed in order to promote health, fight infection and battle
cancer. These substances can sometimes cause certain cells to acquire intracellular
damage resulting in alterations to DNA structure, RNA stability, protein formation or
function. Repair processes can fix certain types of intracellular nucleotide damage;
different processes are cued for either single-strand or double-strand DNA lesions. Cell
cycle checkpoints halt cell division until DNA damage is repaired so that mutations are
not inherited by future generations. Single-strand break (SSB) repair can fix DNA
adducts, depurination/ depyrimidation, certain levels of damage due to exposure to
ultraviolet light, and reactive oxygen species. SSB relies on the complementary strand to
provide a template reference to add back the correct bases or nucleotides. Double-strand
breaks (DSB) are repaired by two general processes: non-homologous end joining (with
loss of information) and sister chromatid homology (without loss of information). Once
SSBs and DSBs have been repaired, replication and transcriptional processes can proceed
within the cell [1]. If parental DNA damage is too great, cells often undergo
programmed cell death or apoptosis through Fas, perforin/granzyme, or mitochondrially
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mediated death pathways involving caspases and release of cytochrome c [2]. However,
accumulated mutations sometimes enable a cell with significant damage to overcome cell
cycle checkpoints and become immortal. Unregulated growth and proliferation of these
immortal cells can result in either benign or malignant tumors. Primary malignancies
have the potential to release metastases that can travel to distant parts of the body via the
bloodstream and setup secondary or satellite tumors.

1.2 Prevalence of Cancer

According to the American Cancer Society, the number of new cancer cases
proposed for 2009 in the United States is about 1.5 million and in South Carolina alone is
over 22,000. Nearly 600,000 Americans are expected to succumb to their cancer this
year with just over 9,000 deaths expected in the state, equating to one death in every four
due to cancer. There is an overall 66% survival rate for the period spanning 1996-2004
with an NIH estimated loss of over $220 billion due to cancer and its sequelae including
costs associated with lost productivity, incidentals, and death, resulting in a significant
impact on human livelihood and economy [3]. With nearly 150,000 cases in the United
States and an estimated 50,000 deaths nationwide, colon cancer accounts for 9% of all
cancer deaths. In both men and women, colorectal cancer is the third most common
cancer. In the state of South Carolina, 2150 new cases and 780 deaths are estimated for
colorectal cancer for 2009. Colon cancer is notoriously chemoresistant and one of the
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reasons for cancer treatment failure and/or patient death is the phenomenon of multiple
drug resistance [4].

1.3 Multiple Drug Resistance

Multiple drug resistance (MDR) in eukaryotic tumor cells has become an
increasingly difficult problem facing scientists and healthcare workers a propos the
treatment and eradication of cancer since the inception of antibiotic use in the 1950s with
subsequent over-use later in the century [5, 6]. MDR has been observed both in vivo and
in vitro and its major causes include altered cell cycle checkpoints, increased damage
repair, apoptotic failure, and efflux-mediated reduced drug accumulation, which is the
subject of this study [7-9]. Other causes of drug resistance include: decreased lysosomal
and endosomal pH, increased cellular pH, increased drug metabolism, decreased plasma
membrane potential, increased plasma membrane conductance to chloride and adenosine
triphosphate (ATP), increased rate of vesicle transport, and activation of the glutathione
system [10]. Chemotherapeutics, in order to be successful in killing cancer cells, must be
able to enter the cancerous cells at a high enough dose to affect killing. Prior to (innate
MDR; such as in renal and colorectal carcinomas) or in response to (acquired MDR; such
as leukemia/lymphoma, ovarian, and breast cancers) these drug treatments, cells can
upregulate certain genes leading to increased expression of a number of proteins known
as efflux pumps that pump out agents undesirable to the cell, thus lowering the
intracellular effective dose and increasing drug clearance from cells [11-13]. With
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exposure to a single type of drug, cancer cells can become resistant to an increased
number of structurally diverse drugs [14, 15]. There are two postulates as to the
mechanism of acquired drug resistance: the first is that chemotherapeutic drugs select for
the small population of intrinsically drug-resistant cells which inevitably overgrow the
drug-sensitive cells leading to overall remission problems or occurrence of additional
tumors; and secondly, drug therapy itself induces upregulation of the mdr1 gene which
encodes an efflux pump known as Phospho-glycoprotein (P-gp) [12]. The linkage
between drug resistance and chemotherapy failure/reduced efficacy prompted efforts to
determine MDR methodologies [11, 12]. Establishment of MDR has been accomplished
in part by the ATP-binding cassette proteins, specifically P-gp, which mediates the “most
important component of clinical multidrug resistance” [16, 17]. Presence of P-gp in
many human cancers is a negative prognostic factor and has been “correlated with tumor
aggressiveness, metastatic potential and advanced disease” with the highest levels of
expression seen in renal and colon cancers [11, 18-20]. Originally depicted by Juliano
and Ling in 1976 in Chinese hamster ovary cells selected for resistance to colchicine,
resistance to this drug was originally surmised to be due to some alteration in the plasma
membrane, but a significant correlation was found among drug resistance and P-gp [21].

1.4 The ATP-Binding Cassette Gene Family

The ATP-binding cassette (ABC) gene family encodes transmembrane phosphoglycoproteins that have variable α-helical transmembrane domains and ATP-binding
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capacity with the function of actively extruding intracellular compounds from the cell
against a concentration gradient [11, 22, 23]. To date, 49 ABC transporters have been
recognized in humans and these are grouped into seven classes (A-G) based on sequence
similarity [24]. Genetic diseases resulting from mutations in these ABC genes include
cystic fibrosis, Tangier disease, anemia, liver failure, and retinal degeneration [1]. One
member of ABC is the mdr1 gene, also known as abcb1; it belongs to the B (MDR/TAP)
subfamily and is located at 7q21.12. The mdr1 gene includes 29 exons with 18 predicted
alternative exons and 32 confirmed introns (ten are alternative) that encode 4.9 kb of
mRNA that is over-expressed in highly drug-resistant sublines and in some normal
tissues [25-27]. “ABCB1 was the first human ABC transporter cloned and characterized
through its ability to confer a MDR phenotype to cancer cells” [28]. Primary transporters
are typically ATPases, like ABC, and are distinguished from secondary transporters that
“couple drug efflux with proton or sodium ion translocation” via proton motive force and
are usually found in yeast and bacteria [29].

mdr1 is regulated by two promoters: one is located upstream and the other
“proximal” promoter is located downstream of the start site within the first exon; the
majority of the mdr1 transcripts originate from this latter site that lacks a TATA box [30].
Activation of the promoter is accomplished through a complex interaction between
transcription factors (MAPKs, Sp1, NF-Y, YB-1, c-fos, c-jun, heat shock consensus
element 70, alternative p63/p73 element, the tumor suppressor p53 and the protooncogene c-raf kinase), DNA binding sites (including cis-acting motifs like GC boxes,
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inverted CCAAT or Y-boxes, the AP-1 site, CCAAT/enhancer-binding protein β binding
motif), and many post-translational modification events including chromatin
reorganization and epigenetics that differ depending on the cell line or cancer in question
[12, 27, 31-40]. mdr1 promoter-reporter constructs have elucidated that nucleotides -134
to +286 from the transcription initiation site are required for basal (non-induced) mdr1
promoter activity whereas “sequences 3’ to the start site are necessary for proper
initiation of transcription” [30]. Hyper-methylation of GC-rich CpG dinucleotides (CpG
islands) in chromatin, an epigenetic mechanism leading to transcriptional silencing, may
negatively regulate the mdr1 promoter [30]. Methylation may work in conjunction with
the assembly of other repressive complexes that bind to the methyl groups; association of
methyl-CpG-binding protein-2 has been shown to be a strong transcriptional repressor
[41]. Demethylation of the mdr1 promoter has been shown to occur during
chemotherapy which may select for hypo-methylated clones [42].

mdr1 encodes the protein P-gp, previously termed PGY1, CD243, ABC20, CLCS,
and GP170, which is a 170,000 dalton (Da) transmembrane protein composed of 1280
amino acids. The polypeptide contains two similar halves of six transmembrane
segments separated by an intracellular nucleotide-binding domain (NBD; an ATPbinding domain) with another NBD at the carboxyl terminus [22]. P-gp is postulated to
exist as both a monomer and an oligomer, and interconversion between these
configurations may change the capability of the protein to interact with different drugs,
thus conferring the protein a greater ability to coadjute with a much wider variety of

6

substrates and possibly also to aid in escape from treatment modalities [43]. The NBDs
of both the N- and C- terminal halves of P-gp contain Walker A (P-loop) and Walker B
sequences separated by a linker dodecapeptide called an ATP signature motif. These two
Walker motifs may alternate in ATP hydrolysis leading to two major protein
conformations: nucleotide-bound and nucleotide-absent. The cysteines of one NBD Ploop motif may interact with those of the ABC signature motif of the other NBD inducing
a sliding motion allowing interconversion between the conformations resulting in drug
translocation [43, 44]. Further ATP hydrolysis is required to return the protein back to
the original conformation. Assembly of P-gp appears to be chaperoned by calnexin as
elucidated through recombinant P-gp transmembrane domain experiments [38, 45].
Glycosylation of the N-terminus aids in translocating P-gp to the plasma membrane
following protein synthesis and post-translational modification [46].

The current consensus is that P-gp acts as an ATP-dependent plasma membrane
vacuum cleaner that effectively extrudes compounds from the cytoplasm and/or prevents
certain substances from entering the cytoplasm by intercepting them in the plasma
membrane and flipping them from the inner leaflet to the outer leaflet where diffusion out
of the cell can take place. For intracellular accumulation to occur, the rate of passive
diffusion of substances across the plasma membrane must surpass the active drug efflux,
such as that of the action of P-gp.
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In all, there are over 100 drug transporters with similar homology to P-gp in both
eukaryotes and prokaryotes, including full and half transporters, that span archaebacteria,
bacteria, yeast, plants, insects, and animals [43]. Mice, hamsters and humans contain
more than one mdr1 gene as revealed through genetic analysis; the “second human MDR
gene is designated MDR3 also called MDR2 which encodes a 4.1-4.5 kB species of RNA
with high degree of homology” to MDR1 although these are non-drug-transporting Pglycoproteins whose function in human seems to be transport of phosphatidylcholine by
liver bile canaliculi [22, 27, 43]. Additionally, P-gp shares homology with human
MRP1-5 of the MRP family (albeit with different glycosylation profiles- the first
extracellular loop of P-gp is heavily N-glycosylated whereas the fourth extracellular loop
of MRP4 and MRP5 is similarly glycosylated) [22, 29]; human BCRP, a half-transporter
homodimer with just six transmembrane segments, an N-linked NBD, and a glycosylated
C-terminal loop [22]; murine MDR1a/1, MDR1b, and MDR2a/MDR3 [22, 27]; hamster
PGP1 and PGP2 [27]; Lactococcus lactis LmrA [29]; Bacillus subtilis BmrA, Vibrio
cholera VcaM, Lactobacillus brevis HorA [47]; and E. coli MsbA (a half-transporter)
[29, 48].

Active efflux in bacteria was first detected in 1980 in E. coli to tetracycline 1 and
as of 2003 five families of multidrug efflux pumps can be found in prokaryotes that are
able to confer resistance to clinically relevant drugs [48, 49]. In prokaryotes, these
transporters are usually encoded within an operon [43].
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1.5 P-glycoprotein Substrate Properties

Though P-gp has wide substrate transport capabilities with respect to structure,
charge, and pH, the most efficiently transported substances are organic and between 2001900Da, neutral or slightly basic, and amphipathic [22, 27]. Some substrates include
vinca alkaloids, anthracyclines, hydroxyurea, alkylating agents, antimetabolites, and
taxanes [11]. Platinum compounds have not been found to be substrates of P-gp.

Experimental evidence has suggested the plausibility of both halves of the P-gp
molecule interacting together to form a major drug interaction pore that may contain
many different sites for drug recognition and binding. Mutational studies have found that
transmembrane segments 5-6 and 11-12 are essential for drug substrate specificity and
lead to successful drug interaction [50].

Shapiro and Ling described two major binding sites/pockets within the P-gp
pharmacophore: one named the “H site” for its ability to bind the fluorescent dye Hoechst
33342 and the other the “R site,” capable of binding rhodamine 123 [51]. While there
may be two major pockets, induced fit and cooperative binding among compounds may
play a role in the ability of P-gp to bind such a wide variety of substrates.
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1.6 Efflux Pumps

Efflux pumps are ubiquitous throughout the human body and are clustered at sites
of drug metabolism (such as in the intestine and liver), sites of secretion, and on the
blood-luminal surfaces of barriers (blood-brain, blood-testicle, blood-nerve) where
interaction of substances is very highly regulated as a way to reduce xenotoxic damage to
sensitive tissues [11, 22]. Knockout of murine mdr1 led to delay of drug clearance and
increased toxins in many tissues including the brains of these mice [30, 52]. Schinkel
and Jonker reported that the presence of P-gp leads to faster clearance of IV-administered
drugs from plasma than when P-gp is absent [22]. In small and large intestinal
epithelium, efflux pumps normally extrude substances (such as toxins from intestinal
bacteria) into bile or into the intestinal lumen in a net detoxifying excretory fashion to
keep them out of the blood supply. Efflux pumps are normally found in the proximal
tubules of the kidney, pancreas, trachea, in capillary endothelia in the brain, the
endoplasmic reticulum, mitochondrial membrane, Golgi, and in lysosomes [22]. Nascent
proteins ready for localization or targeting to the plasma membrane may represent a
portion of the efflux pumps present in the endoplasmic reticulum and Golgi.
Additionally, P-gp in the Golgi flips glucosylceramide to “enhance neutral
glycosphingolipid synthesis” [53, 54]. Some hematopoietic cells also express P-gp,
which may have a role in cell proliferation and differentiation by effluxing a regulatory
molecule [43, 55].
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1.7 Modalities Employed to Overcome MDR

Several methods are currently being employed to overcome MDR. Antisense
oligonucleotides to downregulate ABC genes or enzymes through RNA interference or
anti-mdr1 ribozymes and antigene therapy in the form of treatment with triplex-forming
oligonucleotides conjugated to anticancer drugs are some examples; however, delivery
methods for these treatments are still being optimized [56-60]. Increasing the sensitivity
of cancer cells to chemotherapeutic drug treatment can also be accomplished by the use
of anti-cancer drugs. Several generations of drugs have been developed to overcome the
MDR phenomenon including first and second generation chemotherapeutics in addition
to specific P-gp inhibitors. First generation drugs that were both inhibitors and substrates
of P-gp weren’t designed specifically to overcome MDR and they often caused
detrimental side effects, like immunosuppression, as seen by treatment with cyclosporin
A [61]. Second-generation drugs that were typically analogs of first-generation drugs,
were “more inhibitor-specific” and designed to reduce side effects; unfortunately even
though these more potent and less toxic drugs exhibited success in vitro, they were poor
in vivo inhibitors due to pharmacokinetic interactions, such as the cardiotoxicity exhibited
by treatment with R-verapamil [22]. Many of these second generation drugs also led to
poor plasma concentrations once in the body [22, 61]. More recently high MDR
transporter affinity drugs have been developed with efficiency at very small
concentrations and are currently in clinical trials [61]. Hydrophobic drugs like vinca
alkaloids (vinblastine, vincristine), anthracyclines (doxorubicin, daunorubicin),
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actinomycin D, etopside (an epipodophyllotoxin) and paclitaxel (a taxane) diffuse freely
across the plasma membrane [7]. SDZ PSC 833, a cyclosporin analog with high affinity
is very slowly transported and also inhibits CYP3A4, involved in clearance of drug
substrates [22]. Inhibition of this metabolic enzyme can lead to drug toxicity if the drug
is not properly metabolized. Another drug, GF120918, has effects on both P-gp and
BCRP and has been shown to be administered orally at high doses [22]. XR9576 and
OC144-093 have also shown potential to be good inhibitors with the ability to be
administered orally and intravenously [22]. However, these systems are often expensive,
time consuming, and difficult to develop. Despite the ability of recently developed
inhibitors to overcome MDR and kill tumor cells, they often have too low bioavailability
or too high toxicity to be given safely to patients [60]. Coadministration of a safe P-gp
inhibitor alongside a chemotherapeutic could have potential synergistic effects such as
successful killing of tumor cells with an ultimately lower dose of chemotherapeutic
administered to patients. Therefore, since current P-gp inhibitors have been less than
successful based on toxicity to patients, the search for P-gp inhibitors has expanded into
the realm of flora-based natural health products in the expanding field of Complementary
and Alternative Medicine.

1.8 The Search for an MDR Inhibitor

Increasing numbers of cancer patients have begun taking natural health products
(NHPs) to supplement their cancer therapy regimens. In fact, roughly a third of
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prescription drug users also take herbal dietary supplements [62]. Studies concerning the
anti-cancer properties and interactions of these NHPs with the chemotherapeutic drugs
are becoming more prevalent, but still aren’t numerous considering the vast array of
NHPs available over-the-counter. Several plants and plant components have recently
been found to contain anti-tumor compounds. Zupko and colleagues found that alkaloids
derived from the tropical Amaryllidaceae were found to have anti-cancer properties [24].
Devil’s Claw (Harpagophytum procumbens), a South African plant, was recently
reported to have anti-P-gp properties whereas its major active component, harpagoside, a
glycoside, in its pure form was found to be ineffective against P-gp [63]. Carnosic acid,
an antioxidant component of rosemary, has been found to decrease mdr1 gene expression
and reverse MDR in multidrug resistant leukemia cells [64]. A phenylbutenoid
derivative of Zingiber cassumunar Roxburgh, an Indian ginger, has been found to reverse
P-gp-mediated MDR [65]. Additionally, the liverwort Asterella angusta contains
dihydroptychantol A, a macrocyclic bisbibenzyl that was shown to inhibit P-gp function
and expression in MDR leukemia cells [66].

Stermitz and colleagues found a “potent MDR inhibitor” in a berberine-containing
plant, Berberis fremontii [67]. The search for similar inhibitors expanded to other
berberine-containing plants. Abidi and colleagues found evidence to suggest the
presence of an MDR inhibitor in the root of goldenseal [68]. Leaf extracts of goldenseal
have been used to potentiate sublethal amounts of ciprofloxacin in bacteria
overexpressing NorA, a bacterial homolog of mdr1 belonging to the Major Facilitator
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Superfamily of secondary transporters leading to a decrease in the minimum inhibitory
concentration (MIC) of the drug (unpublished data).

1.9 Hydrastis canadensis

Hydrastis canadensis, otherwise known as goldenseal of the family
Ranunculaceae and a perennial relative of the buttercup, is a neutraceutical herb grown in
the southeastern United States that is often taken for various ailments including mouth
sores, gastrointestinal turmoil, and eye maladies in addition to its use as a prophylactic
mouthwash or douche. Native Americans’ use of H. canadensis to fight conjunctivitis
and as an antiseptic earned it such names as yellow root and eye root due to its healing
properties and the yellow color of its roots. “The first medicinal use of goldenseal root
extract was reported in the late 1700s for the treatment of what was thought to be cancer
and for inflamed eyes” [69]. Later in the 18th century, this herb was renamed goldenseal:
“golden” based on the color of the root and “seal” for the likeness of the yearly stem
rings to wax seals on written letters. Goldenseal root has been shown to have
immunostimulatory properties, including increasing the amount of IgM and IgG
antibodies when taken [70, 71]. Commercially available goldenseal is sold as whole
plant, root/rhizome, or leaf/stem extracts prepared as a liquid, tablet/caplet, or cream
although the most common is goldenseal root as a tablet/caplet. Experimental studies of
possible synergism existing among different combinations of root/rhizome and leaf/stem
ratios of goldenseal have not been reported in the literature, nor has the effectiveness of
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different preparations (liquid, solid, powder) as far as exhibiting the lowest toxicity with
greatest activity been determined.

1.10 Secondary Metabolites of Goldenseal

In addition to alkaloids, the family Ranunculaceae also contains the secondary
metabolites protoanemonin and glycosides. Berberastine, meconin, chlorogenic acid,
phytosterins, and resins, albumin, starch, fatty matter, sugar, lignin, and volatile oil (in
the root) are other compounds found in the plants belonging to this family. Glycosides
belong to the terpenoid group of secondary metabolites and are sterol derivatives thought
to function as herbivore deterrents [72]. Several glycosides can cause considerable
toxicity to herbivores, disrupting the Na+/K+-ATPase pump found in vertebrate hearts, or
releasing cyanide through mastication and amalgamation of other plant components [72].
Lignin formed through peroxidase-mediated oxidation of alcohols forming free radicals
that react with each other to form these woody molecules, performs a mainly structural
function, but due to its water insolubility and covalent linkage, decreases digestibility of
cellulose and may also, with other phenolic derivatives, slow the rate of fungal-mediated
cell wall degradation [72].
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1.11 Major Alkaloids of Hydrastis canadensis

The majority of alkaloids, such as berberine, in plants are found in the roots,
tissues most vulnerable in terms of plant fitness with respect to microbial attack rather
than in the leaves, petals or shoots [73]. Nitrogen-containing alkaloids for the most part
exhibit antimicrobial properties, though most are toxic in high doses. The two major
bioactive isoquinoline alkaloids present in goldenseal, berberine and hydrastine, have
been variably studied singly with berberine being the most studied of the two alkaloids.
In tumor cells, low doses of berberine (see Figure 1), a P-gp substrate and weak antimicrobial, localize specifically to intracellular mitochondria [74].

Figure 1. Structure of Berberine.

With increasing doses, berberine also localizes to the nucleus where it strongly interacts
with DNA causing down-regulation of genes including mdr1 [74]. Compared to
goldenseal root, the anti-tumor effects of berberine (and other pure alkaloids) are not as
great, suggesting that other components within the goldenseal interact synergistically to
give better effects than pure compounds alone [68]. Oral bioavailabilities of berberine
and hydrastine have been reported to be low in animal studies, though “little is known
about [the] pharmacokinetics of goldenseal alkaloids in humans” [62, 70].
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CHAPTER TWO
MATERIALS AND METHODS

2.1 Determination of the Minimum Inhibitory Concentration of Goldenseal and Berberine
Against Salmonella typhimurium Strain TA100

MICs of goldenseal and berberine to TA100 cells in the presence and absence of
S9 were determined using a modified microbroth dilution method for liquid preparations
of goldenseal and berberine and a modified macrobroth dilution method for powder
preparations of goldenseal. For the microbroth dilution method, 104 TA100 cells were
added to round-bottom wells of 96-well plates containing 200µL media and goldenseal
(or berberine) preparations (with or without S9) and allowed to incubate for 18-24 hours
at 37°C. For the macrobroth dilution method, the amounts of TA100 cells, goldenseal,
and S9 preparations were scaled up to volumes of 2mL and added to 5mL borosilicate
glass tubes. Components were added, tubes vigorously vortexed to mix the goldenseal
powder thoroughly, and incubated at 37°C for 18-24 hours with shaking to ensure proper
aeration of the media and interaction of the cells with the goldenseal powder. Tubes were
removed from the incubator to allow the powder to settle before determination of MIC
concentrations based on media turbidity compared to control tubes lacking goldenseal.
These assays were performed at least twice with triplicate microbroth samples and
duplicate macrobroth samples.
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2.2 Ames Assay

Salmonella typhimurium His- auxotrophic strain TA100 containing a base-pair
point mutation in the histidine fabrication gene hisG46 (GTG GTC GAT CT*C GGT
ATT where T occurs in prototrophs and C appears in mutant auxotrophs) was used in the
standard plate incorporation Ames assay as described by Bruce Ames in 1975 and revised
by Maron & Ames in 1983 [75, 76]. Strain TA100 is just one of many strains commonly
used in the Ames assay (for other strains, see Table 1). These strains recognize base-pair
substitutions, such as by TA100, or frameshift mutations. Different strains can be used
concurrently to get a better idea of the mutagenic potential of a particular substance.

Table 1. Selection of Salmonella typhimurium Strains Used in Ames Assays
Mutational Event

S. typhimurium Strains

Base-pair substitution

TA100, TA102, TA1530, TA1535

Frameshift

TA97, TA98, TA1531, TA1532, TA1534, TA1536, TA1537, TA1538

In addition to being histidine-dependent, TA100 cells contain certain
modifications to increase assay sensitivity: an rfa mutation increasing pore sizes within
the lipopolysaccharide barrier to influx larger substances, a deletion of the DNA excision
repair system with biotin dependence (∆uvrB), and an R factor plasmid (pKM101)
conferring ampicillin resistance for selection purposes. TA100 cells received as frozen
permanents were verified for these characteristics, grown on a master plate at 37°C, kept
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at 4°C for no more than 2 months at a time and used to setup overnight cultures. Cells
from the master plate were transferred to tubes containing Oxoid nutrient broth #2 for 1015 hours to reach exponential growth phase at 37°C for assays. Initial cell concentration
was measured by optical density at 600nm and adjusted to 1x108 cells/mL. Bottom agar
consisting of minimal glucose with salts and 1.5% Noble agar was overlaid with 2mL of
top agar (containing sodium chloride, 0.6% Noble agar, with trace amounts of 0.05mM
histidine and 0.05mM biotin), 1x107 cells, and up to 100µL goldenseal/berberine.
Goldenseal liquid (organic grain ethanol-based), goldenseal solid (DMSO-based), and
berberine were autoclaved, diluted to appropriate concentration, and incorporated into the
top agar. Goldenseal powder was added to glass Petri dishes, autoclaved, and then 30mL
of bottom agar was mixed with the powder. Top agar was overlaid once the bottom agar
was set. S9 liver enzymes were added to sodium phosphate buffer, water, glucose-6phosphate, NADP, and S9 salt solution. These enzymes from Aroclor-induced rats were
used to supplement the TA100 cells to see if bioactivation (similar to a trip through the
digestive system) of the agent alters its mutagenic potential. 0.5mL of this solution was
added to each plate via incorporation into the top agar overlay. Overlays were allowed to
set for up to one hour, then plates were inverted and incubated at 37°C for 48 hours.
Colony-forming units were counted with control values within the normal range [77].
Sodium azide was used as a positive control in all experiments.
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2.3 Cell Lines and Cell Culture Maintenance

HT-29 epithelial cells established from the colorectal adenocarcinoma of a 44
year old Caucasian female in 1964 were attained from ATCC (ATCC #HTB-38™) and
maintained in ATCC-formulated McCoy’s 5A media (modified; ATCC #30-2007)
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were
fed with fresh media every 2-3 days, passaged at 90-100% confluence, and subcultured in
1:3-1:8 ratios. Sub-lethal doses of the anthracycline doxorubicin, a common antineoplastic drug, were administered to the HT-29 colon cancer cell line through step-wise
addition from 0.001µg/mL through 1µg/mL in 10x increments to select for doxorubicinresistant HT-29 cells (HT-29/Dox) [78-80]. Selection of drug-resistant cells was
performed in this manner as transfection of cells with P-gp was found to confer
“significantly less efficient drug resistance” than cells selected with step-wise addition of
drugs [81]. These cells were maintained in 1µg/mL doxorubicin-supplemented media
and subcultured similarly to HT-29 cells. CCD-18Co fibroblastic cells established from
the healthy colon of a 2.5 month old African American female were purchased from
ATCC (ATCC #CRL-1459™) at P22 and maintained in ATCC-formulated Eagle’s
minimum essential media (ATCC #30-2003) supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin. Cells were fed with fresh media every 2-3 days,
passaged at 90-100% confluence, and subcultured in 1:2-1:3 ratios.
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2.4 MTS Cell Proliferation Assay for Doxorubicin Tolerance

Cells were seeded in 200µL volumes at a concentration of 1.5x104 cells per well
in a 96-well plate and allowed to attach overnight. Media was removed and doxorubicincontaining media was added to each cell line in concentrations of 0µg/mL, 0.1µg/mL,
1.0µg/mL and 10µg/mL to reflect 0, 1/10x, 1x, and 10x concentrations of the media used
to maintain the HT-29/Dox cells. Doxorubicin treatments were allowed to incubate 24,
48, and 72 hours longer. After the allotted time, media was discarded and wells were
washed with 200µL PBS. 100µL media plus 20µL Cell Titer 96 Aqueous solution
reagent were added to each well and incubated at 37°C. Absorbance490nm was taken after
1, 2, and 3 hours. Cell viabilities of treated cells were determined as a percentage of cell
viabilities of non-treated cells.

2.5 MTS Cell Proliferation Assay for Determination of Goldenseal Liquid MIC

Cells were seeded in 200µL volumes at a concentration of 1.0x104 cells per well
in a 96-well flat-bottom plate and allowed to attach overnight at 37°C. Treatments were
added and plates were allowed to incubate 72 hours longer. Media was discarded and
wells were washed with 200µL PBS. 100µL fresh media and 20µL Cell Titer 96
Aqueous solution reagent were added to each well and incubated at 37°C for 4 hours.
Absorbance was measured in a spectrophotometer at 490nm. Cell viabilities of treated
cells were determined as a percentage of cell viabilities of non-treated cells.
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2.6 Genomic DNA Extraction and Purification

Genomic DNA extraction and purification were performed using the Invitrogen
PureLink™ Genomic DNA Mini Kit. Briefly, up to 5x106 cells were harvested and
resuspended in 200µL PBS with 20µL proteinase K and 20µL RNase A. Cells were
vortexed briefly and incubated 2 minutes before the addition of 200µL PureLink™
Genomic Lysis/Binding buffer. Following incubation at 55°C for 10 minutes to digest
protein, 200µL 100% ethanol were added to the lysate. Purification: Lysates were
transferred to spin columns and centrifuged at 10,000 x g for 1 minute. Spin columns
were transferred to clean collection tubes, 500µL Wash buffer 1 was added to each, and
tubes were centrifuged at 10,000 x g for 1 minute. This step was repeated with the
addition of 500µL Wash buffer 2, and then centrifuged at maximum speed (14,000 x g)
for 3 minutes. Spin columns were transferred to clean collection tubes. 200µL
PureLink™ Genomic Elution buffer were added to the columns and incubated for 1
minute, then centrifuged at max speed for 1 minute. Spin-through was re-eluted during a
subsequent centrifugation at max speed for 90 seconds and used immediately, stored
short-term at 4°C, or stored at -20°C. Absorbance was measured at 260nm with a
conversion factor 1.0 absorbance260nm = 50.0µg/mL for double-stranded DNA.
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2.7 Polymerase Chain Reaction

The polymerase chain reaction (PCR) was performed using NovaTaq PCR PLUS
kit with Optimization buffer per manufacturer instructions. A reaction mixture
containing the following components per tube was prepared: 5µL NovaTaq + MgCl2, 1µL
dNTPs, 1µL 10µM forward primer, 1µL 10µM reverse primer, 0.25µL DNA polymerase,
50ng DNA, and water to bring volume to 50µL. Control tubes lacking DNA polymerase
or DNA template were also setup. PCR tubes were placed into an MJ Mini thermal
cycler and run under the following conditions: denaturation at 94°C for 1 minute,
annealing at 53.8°C for 45 seconds, and extension at 75°C for 1:15. These steps were
repeated for 35 cycles, followed by a final extension at 72°C for 10 minutes. The
amplicons were run immediately on a 2% agarose gel under 70 volts (V) for 60 minutes
for single lane gels or 45 minutes for dual lane gels or stored at 4°C short-term until a gel
could be run. mdr1 forward primer 5’ CAT TGG TGT GGT GAG TCA GG 3’ (cDNA
1523-1542; Tm = 55.8°C) and reverse primer 5’ CTC TCT CTC CAA CCA GGG TC 3’
(cDNA 1679-1698; Tm = 56.8°C) span intron 14 leading to a band of 508 base pairs (bp)
following electrophoresis on an agarose gel. Gene presence was compared to the β-actin
housekeeping gene, forward primer 5’CCC AGA GCA AGA GAG GCA TC 3’ (Tm =
57.7°C) and reverse primer 5’ AGC ACA GCC TGG ATA GCA AC 3’ (Tm = 57.7°C),
giving a band size of 247bp [58, 82]. Both mdr1 and β-actin primer sets were obtained
from Integrated DNA Technologies.

23

2.8 Goldenseal Liquid Treatment Scheme

Cells were seeded into 60mm tissue culture-treated round Petri dishes at a
concentration of 1x106 cells per dish and allowed to attach overnight. Cells were washed
two times with PBS, given fresh media, and goldenseal/berberine equivalent liquid
treatments were added in concentrations of 0, 0.125xMIC, 0.25xMIC, and 0.5xMIC.
Treatments were setup in triplicate and measured after 24, 48, and 72 hours.

2.9 RNA Extraction

RNA Extraction was performed using the Invitrogen FastTrack™ MAG micro
mRNA Isolation Kit as per manufacturer instructions. Briefly, 2.5x105 cells were
pelleted, decanted, and resuspended in lysis buffer L4 and 2.5µL proteinase K using a 21gauge needle to shear the nucleic acid. Tubes were centrifuged at 14,000 x g for 5
minutes (all centrifugations were performed at room temperature). The supernatants
were transferred to fresh tubes and incubated at 45°C for 10 minutes. During incubation,
FastTrack™ MAG beads were mixed and washed three times. Cell lysates and heated
binding buffer B6 were then added to the beads and incubated at 65°C for 2-5 minutes.
Tubes were then rotated for 10 minutes at room temperature. Samples were placed in a
magnetic separator for 1-2 minutes, washed, resuspended, and washed again in wash
buffer 6 then three times in wash buffer 7. Samples were resuspended in 43µL RNAsefree water, incubated at 37°C for 2-5 minutes, inserted into a magnetic separator, and the
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supernatant containing the mRNA was saved in a clean tube. This was followed by a
secondary elution with an additional 7µL water. The respective supernatants were pooled
together and samples were stored at -80°C.

2.10 Real Time Reverse Transcriptase-PCR

Real time reverse transcriptase-PCR (RT-PCR) was used to amplify cDNA
following reverse transcription of the isolated mRNA so that slight differences in gene
expression levels could be easily detected. Use of the Bio-Rad iScript™ One-Step RTPCR Kit with SYBR Green allowed for reverse transcription and PCR to be performed in
one tube with fluorescence of SYBR green measured at the end of each cycle. For onestep RT-PCR, 25µL reaction volumes contained the following per tube: 12.5µL 2X
SYBR green master mix, 0.5µL 10µM forward primer, 0.5µL 10µM reverse primer,
0.5µL reverse transcriptase, 25ng RNA, and water to bring reaction volume to 25µL.
Triplicate samples were run in duplicate under the following conditions: cDNA synthesis
at 50°C for 10 minutes, RT inactivation and initial denaturation at 95°C for 5 minutes,
denaturation for 10 seconds at 95°C and annealing for 30 seconds at 53.8°C for 35 cycles.
Presence of bands and purity of amplification were confirmed by running amplicons on a
2% agarose gel under 70V for 60 minutes for single lane gels and for 45 minutes for dual
lane gels rather than melt curve analyses to confirm correct size and purity of the PCR
products. mdr1 forward primer 5’ CAT TGG TGT GGT GAG TCA GG 3’ and reverse
primer 5’ CTC TCT CTC CAA CCA GGG TG 3’ span intron 14 leading to a band of 174
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bp following electrophoresis on an agarose gel which discerns genomic contamination
from RNA amplification [79]. The β-actin housekeeping gene was amplified using
forward primer 5’ CCC AGA GCA AGA GAG GCA TC 3’ and reverse primer 5’ AGC
ACA GCC TGG ATA GCA AC 3’ to give a band size of 247bp [82]. Analysis utilized
the comparative Ct method (2-[delta][delta]Ct) where [delta][delta]Ct = [delta]Ctsample –
[delta]Ctreference where the sample and references are normalized to the housekeeping gene
(β-actin). The threshold cycle, Ct, is defined as the cycle at which fluorescence crosses
into the exponential phase from the initial linear phase. The standard curve method was
not considered as the amounts of RNA added to the reaction mixture were known.

2.11 UIC2 Shift Assay

P-glycoprotein function was analyzed using a modified UIC2 shift assay. UIC2
(Millipore MAB4334PE) is a monoclonal antibody that recognizes an extracellular
conformational epitope of the P-gp protein [83]. Addition of a substrate, such as
vinblastine, slightly alters the conformation of the epitope recognized by UIC2 which
greatly enhances its binding from around 40% to nearly 100% [55]. The two colon
cancer cell lines were treated with GSL 2:2 at 0, 100µg/mL, 200µg/mL, and 400µg/mL in
triplicate to assess changes in P-gp protein function. For the assay, monolayers were
trypsinized, washed in PBS, brought to concentration, and allowed to incubate at 37°C
for 10 minutes in pre-warmed PBS to maintain physiological conditions. Either 25µM
vinblastine or control diluent were added and allowed to incubate with the cells at 37°C
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for an additional 10 minutes with periodic agitation to engage P-gp. 10µL of 10µg/mL
UIC2-PE or 10µL of 10µg/mL IgG2a-PE (isotype control) were added to each sample
and allowed to incubate for an additional 20 minutes at 37°C to stain cells. Cells were
then washed twice in ice cold Shift Stop Buffer (SSB; PBS + 0.1% sodium azide) then
resuspended in 100µL SSB and transferred to black 96-well plates. Cells were kept on
ice protected from light until fluorescence could be measured following excitation at
488nm and emission at 575nm on an FLX-800I fluorescence microplate reader. Data
was collected using KC4 software. Changes in P-gp expression were calculated by
normalizing the treatments to their respective isotype controls then determining relative
fluorescence compared to the cells + UIC2 treatment [55].

2.12 Potentiation Assay

Cells were seeded in 200µL media at a concentration of 1x104 cells/well and
allowed to attach overnight in 96-well plates. Media was removed and cells were
washed. Vinblastine or vinblastine and GSL 2:2 were added at test concentrations and
media was added to bring the volume of each well up to 200µL. Cells were allowed to
incubate 72 hours. The media was removed and the wells were washed twice with PBS.
100µL media plus 20µL Cell Titer 96 Aqueous solution reagent were added to each well
and incubated at 37°C. Absorbance490nm was taken after 4 hours. Cell death was
determined as a percentage of untreated cells.
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2.13 Cellular Attachment Assay

1x104 cells were seeded into 96-well plates in 200µL, allowed to attach overnight
(“Attached”), and treated with GSL 2:2 or treated with GSL 2:2 during cell seeding (“Not
Attached”). Cells were allowed to incubate 72 hours, then the MTS assay was
performed: media was discarded and wells were washed with 200µL PBS and then
100µL media plus 20µL Cell Titer 96 Aqueous solution reagent were added to each well
and incubated at 37°C. Absorbance490nm was measured after 4 hours. Cell death was
determined as a percentage of untreated cells.

2.14 Statistical Analysis

Numbers expressed as mean ± standard deviation were analyzed by Student’s T
test. Values were considered significantly different according to p values <0.05.
Notations were also made when p<0.01.
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CHAPTER THREE
RESULTS

3.1 The Mutagenesis of Goldenseal According to the Ames Assay

3.1.1 Description of the Ames Assay

The Ames assay was first described by Bruce Ames in 1975 and has undergone
several modifications since that time [75, 76]. This assay determines the mutagenic
potential of substances using a bacterial system that can be supplemented with S9 liver
enzymes from Aroclor-induced rat livers to determine if metabolic bioactivation of the
substance alters its mutagenic potential. The bacterial strain used in this assay,
Salmonella typhimurium strain TA100, is auxotrophic for the amino acid histidine via a
single bp mutation. These auxotrophic organisms will not survive unless a histidine
supplement is added to the media. In the Ames assay, if a mutagenic substance capable
of inducing base pair alterations is incubated in the presence of these auxotrophs, chances
are good that it will alter that one nucleotide back to a thymine and enable the TA100
cells to synthesize histidine, causing the descendants of that cell to be prototrophic, thus
allowing them to survive and form a colony on minimal media in the absence of histidine
supplementation. A certain number of cells are able to revert spontaneously back to
histidine prototrophs and are deemed spontaneous revertants.
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3.1.2 Assay Setup

TA100 cells were plated onto minimal media in a standard plate incorporation
assay with the test agent (goldenseal or berberine) with or without S9 enzymes in
triplicate or in some cases in sextuplicate. The plates were allowed to incubate for 48
hours at 37°C. Negative control plates were included in each assay and spontaneous
revertants were counted from these plates. Sodium azide, a common preservative, was
included as a positive control in each experiment which elicited colonies in number
several fold higher than the numbers found on the spontaneous revertant plates.

3.1.3 Forms and Ratios of Goldenseal

Three different forms of goldenseal were received from Sleepy Hollow Herb
Farm, Dalton, Georgia and were tested in the Ames assay: an organic grain ethanol-based
liquid extract (GSL), a ground powder (GSP), and a partially dried solid (GSS) with the
consistency of a lotion. Each of these preparations was tested in different ratios of
root/rhizome to leaf/stem: 4:0 (all root/rhizome), 3:1 root: leaf, 2:2 (equal parts), 1:3 root:
leaf, and 0:4 (all leaf/stem). Each of these five ratios was provided in liquid and powder
forms; one container of all root solid and one of all leaf solid were supplied and these
were mixed for the assay.
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The concentrations of goldenseal used in the Ames assay were determined based
on the minimum inhibitory concentration of goldenseal used to inhibit growth of the
TA100 cells. Table 2 shows the MICs for each of the goldenseal preparations and ratios
without and with S9.

Table 2. MICs of Goldenseal to TA100
Ratio R:Lᶲ

4:0

3:1

2:2

1:3

0:4

GSL

No S9

430 (75.6†)

430 (62.4)

430 (50.9)

430 (36.8)

430 (23.6)

(µg/mL)

With S9

215 (37.8)

430 (62.4)

430 (50.9)

430 (36.8)

430 (23.6)

GSP

No S9

10 (0.4)

10 (0.3)

10 (0.3)

15 (0.3)

15 (0.2)

(mg/mL)

With S9

10 (0.4)

10 (0.3)

10 (0.3)

15 (0.3)

15 (0.2)

GSS

No S9

430 (40.6)

430 (34.8)

430 (29.0)

430 (23.2)

430 (17.4)

(µg/mL)

With S9

215 (20.3)

430 (34.8)

430 (29.0)

430 (23.2)

430 (17.4)

ᶲRoot/rhizome: Leaf/stem ratio. †Equivalent berberine content is noted in parentheses.

For each ratio, five different concentrations of goldenseal were assayed in the
Ames assay: 0.125xMIC, 0.25xMIC, 0.5xMIC, MIC, and 2xMIC. These concentrations
were tested in order to assay a range of concentrations wherein sublethal doses of
goldenseal were added to TA100 cells to get a true measure of the mutagenicity of
goldenseal.
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3.1.4 Berberine

In addition to goldenseal, berberine, one of the major alkaloids of goldenseal, was
assayed at a percentage of each of the goldenseal concentrations based on the values
found in Table 3. These berberine sulfate equivalents appear in parentheses in Tables
4-9.

Table 3. Components of Goldenseal (lot 1044)
Goldenseal Liquid Extract

GSP

GSS

R:Lᶲ

EtOH

Dry Weight

Berberine

Berberine

Berberine

Berberine

Ratio

%

mg/mL

mg/mL

%

%

%

4:0

53.0

8.7

1.53

17.59

3.88

9.45

3:1

54.5

9.1

1.32

14.51

3.26

8.10

2:2

56.0

9.3

1.10

11.83

2.65

6.75

1:3

57.5

10.4

0.89

8.56

2.04

5.39

0:4

59.0

12.2

0.67

5.49

1.43

4.04

ᶲRoot/rhizome: Leaf/stem ratio

3.1.5 Mutagenic Potential

The determination of the mutagenic potential of goldenseal and berberine was
based on published standards: a substance was considered to be mutagenic if it caused a
dose response and had a fold change over spontaneous revertants greater than 2 [84, 85].
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Fold change is determined by dividing the number of colonies on the test plates by the
number of colonies on the negative control plates (the spontaneous revertants).

3.1.6 Ames Assay Results

3.1.6.1 Goldenseal Liquid in the Absence of S9

The results of the Ames assay for GSL (lot 1044) without S9 are shown in Table
4. Berberine sulfate equivalents are in parentheses for each ratio and each goldenseal
concentration. The sodium azide positive control resulted in a fold change of 127±16.6.
For the 4:0 ratio of goldenseal, fold changes ranged from 0.1±0.1 (at 2xMIC) to 1.3±0.2
(at 0.125xMIC), with higher doses leading to lower fold changes. For this same ratio of
berberine equivalents, there was a similar reverse dose response ranging from 0.1±0.1 (at
2xMIC) to 1.2±0.1 (at 0.125xMIC) without a fold change greater than 2. Fold changes
for the 3:1 goldenseal ratio ranged from 0.1±0.1 (at 2xMIC) to 0.9±0.2 (at 0.125xMIC)
with fold changes of berberine equivalents ranging from 0.3±0.3 (at 2xMIC) to 1.0±0.1
(at 0.125xMIC and at 0.5xMIC). The 2:2 ratio of liquid goldenseal elicited fold changes
between 0±0 (at 2xMIC) and 1.2±0.1 (at 0.125xMIC) with berberine fold changes from
0±0 (at 2xMIC) to 1.1±0.3 (at 0.5xMIC). Fold changes for the 1:3 goldenseal liquid ratio
ranged from 1.2±0.1 (at 2xMIC) to 1.7 (at 0.125xMIC, 0.5xMIC, and at MIC) and
berberine equivalents had fold changes from 0.4±0.2 (at 2xMIC) to 1.7±0.6 (at MIC).
The 0:4 goldenseal liquid ratio resulted in fold changes ranging 1.0±0.1 (at 2xMIC) to
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1.6±0.6 (at 0.5xMIC) while its berberine equivalents ranged 0.6±0.2 (at 2xMIC) to
2.1±1.2 (at 0.5xMIC). Even though the berberine equivalent fold change at 0.5xMIC was
greater than 2, there was no dose response. Based on all of these results, goldenseal
liquid in the absence of S9 elicited no dose responses with fold changes greater than 2,
therefore none were considered mutagenic. Similar conclusions were drawn for the
berberine sulfate equivalents.

Table 4. Fold Changes of GSL in the Absence of S9 Activation
R:Lᶲ
Ratio

0.125xMIC

0.25xMIC

0.5xMIC

MIC

2xMIC

1.3±0.2
4:0
(13.31%) (1.2±0.1†2,6)

1.1±0.12,6
(0.9±0.14,6)

0.9±0.41
(0.8±0.26)

0.6±0.42
(0.6±0.2)

0.1±0.12
(0.1±0.16)

0.4±0.12,6
(0.9±0.12,4,6)

0.3±0.42
(1.0±0.12,4)

0.3±0.32
(0.4±0.12)

0.1±0.12
(0.3±0.32)

3:1
(12.01%)

0.9±0.22,6
(1.0±0.12)

1.2±0.12,5
0.8±0.22,5
1.1±0.7
0.5±0.32
0 ±02,5
2:2
2,4,6
2
2
(0.9±0.2 )
(1.1±0.3)
(0.5±0.4 )
(0±02)
(10.23%) (0.9±0.2 )
1.7±0.12,5
1.6±0.12
1.7±0.33
1.7±0.45
1.2±0.16
1:3
2,4,6
2,4,5
(1.1±0.1 )
(1.6±0.5)
(1.7±0.6)
(0.4±0.22,4,5)
(9.26%) (0.9±0.2 )
1.2±0.11,5
1.1±0.12
1.6±0.65
1.1±0.3
1.0±0.12,6
0:4
(1.5±0.24,6)
(2.1±1.2§)
(1.4±0.65)
(0.6±0.22,4,5)
(8.17%) (1.6±0.24,6)
ᶲRoot/rhizome: leaf/stem ratio. †Berberine equivalents are in parentheses. n=6.
§Fold change > 2.0. Significant difference from spontaneous revertants (1p<0.05,
2

p<0.01); from goldenseal (3p<0.05, 4p<0.01); from presence of S9 (5p<0.05, 6p<0.01).
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3.1.6.2 Goldenseal Liquid in the Presence of S9

The results of the Ames assay for GSL (lot 1044) in the presence of S9 liver
enzymes are shown in Table 5. Berberine sulfate equivalents are in parentheses for each
ratio and each goldenseal concentration. The sodium azide positive control resulted in a
fold change of 116±5.1. For GSL 4:0 with S9, fold changes ranged from 0±0 (at 2xMIC)
to 1.9±0.3 (at 0.25xMIC). For this same ratio of berberine equivalents, the fold changes
ranged from 0.6 (at 0.125xMIC and at MIC) to 1.3 (at 0.25xMIC and 0.5xMIC) without a
fold change greater than 2. Fold changes for GSL 3:1 with S9 ranged from 0±0 (at MIC
and 2xMIC) to 1.5±0.2 (at 0.125xMIC) with fold changes of berberine equivalents
ranging from 0±0 (at 2xMIC) to 1.3±0.1 (at 0.25xMIC). GSL 2:2 with S9 elicited fold
changes between 0±0 (at 2xMIC) and 1.4±0.2 (at 0.125xMIC) with berberine fold
changes from 0±0 (at 2xMIC) to 1.3 (at 0.125xMIC and 0.5xMIC). Fold changes for the
GSL 1:3 with S9 ranged from 0.7±0.8 (at MIC) to 1.5±0.3 (at 0.25xMIC) and berberine
equivalents with S9 had fold changes from 0.9 (at 0.5xMIC and MIC) to 1.6±0.2 (at
0.125xMIC). GSL 0:4 in the presence of S9 resulted in fold changes ranging 0.3±0.3 (at
2xMIC) to 1.6±0.3 (at 0.125xMIC) while its berberine equivalents in the presence of S9
ranged 0.6±0.1 (at 0.125xMIC) to 1.0±0.3 (at 0.5xMIC). Based on these results,
goldenseal liquid in the presence of S9 elicited no dose responses with fold changes
greater than 2, therefore none were considered to be mutagenic. Similar conclusions
were drawn for the berberine sulfate equivalents in the presence of S9 at the
concentrations tested.
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Table 5. Fold Changes of GSL in the Presence of S9 Activation
R:Lᶲ
0.125xMIC
0.25xMIC
0.5xMIC
MIC
2xMIC
Ratio
1.2±0.2
1.9±0.32
1.4±0.21
0.3±0.32
0±02
4:0
2,4
1,3
1
(1.3±0.2 )
(1.3±0.1 )
(0.6±0.6)
(0.7±0.12,4)
(13.31%) (0.6±0.2† )
1.5±0.21
1.4±0.4
0.9±1.0
0±02
3:1
0±02 (0±02)
3
1
1
(1.2±0.2 )
(1.3±0.1 )
(0.7±0.3 )
(0.5±0.51)
(12.01%)
1.4±0.22
1.3±0.21
0.9±0.9
0.9±1.0
0 ±02
2:2
(1.3±0.12)
(1.1±0.3)
(1.3±0.4)
(0.4±0.51)
(0±02)
(10.23%)
1.4±0.21
1.5±0.32
0.8±0.9
0.7±0.8
0.9±0.11
1:3
2
2
(1.6±0.2 )
(1.5±0.3 )
(0.9±0.8)
(0.9±0.7)
(1.0±0.4)
(9.26%)
2
1.6±0.3
1.4±0.3
0.8±0.7
0.7±0.5
0.3±0.32
0:4
1,4
3
(0.6±0.1 )
(0.9±0.3 )
(1.0±0.3)
(0.7±0.5)
(0.8±0.11,4)
(8.17%)
ᶲRoot/rhizome: leaf/stem ratio. †Berberine equivalents are in parentheses. n=6.
Significant difference from spontaneous revertants (1p<0.05, 2p<0.01); from goldenseal
(3p<0.05, 4p<0.01).

3.1.6.3 Goldenseal Powder in the Absence of S9

The results of the Ames assay for GSP (lot 1044) without S9 are shown in Table
6. Berberine sulfate equivalents are in parentheses for each ratio and each goldenseal
concentration. Sodium azide resulted in a fold change of 91.0±31.2. For the 4:0 ratio of
goldenseal powder in the absence of S9, fold changes ranged from 0±0 (at 2xMIC) to
1.3±0.3 (at 0.25xMIC). For this same ratio of berberine equivalents, fold changes ranged
from 0±0 (at 0.5xMIC, MIC, and 2xMIC) to 0.6±0.4 (at 0.125xMIC). Fold changes for
GSP 3:1 in the absence of S9 ranged from 0±0 (at 2xMIC) to 1.8±0.1 (at 0.25xMIC) with
fold changes of berberine equivalents ranging from 0±0 (at MIC and 2xMIC) to 1.0±1.2
(at 0.5xMIC). GSP 2:2 in the absence of S9 elicited fold changes between 0±0 (at
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2xMIC) and 1.6±0.3 (at 0.25xMIC) with berberine fold changes from 0±0 (at MIC and
2xMIC) to 0.5 (at 0.125xMIC and 0.25xMIC). Fold changes for GSP 1:3 without S9
ranged from 0±0 (at MIC and 2xMIC) to 1.5 (at 0.125xMIC and 0.25xMIC) and
berberine equivalents had fold changes from 0±0 (at 0.5xMIC, MIC, and 2xMIC) to
0.7±0.7 (at 0.25xMIC). GSP 0:4 in the absence of S9 resulted in fold changes ranging
0±0 (at MIC and 2xMIC) to 1.4 (at 0.125xMIC and 0.25xMIC) while its berberine
equivalents ranged 0±0 (at MIC and 2xMIC) to 0.7±0.3 (at 0.25xMIC). Based on these
results, GSP in the absence of S9 elicited no dose responses with fold changes greater
than 2, therefore none were considered mutagenic. Similar conclusions were drawn for
the berberine sulfate equivalents.

Table 6. Fold Changes of GSP in the Absence of S9 Activation
R:Lᶲ
0.125xMIC
0.25xMIC
0.5xMIC
MIC
2xMIC
Ratio
1.2±0.2
1.3±0.3
0.7±0.46
0.1±0.12,5
0±02
4:0
(0.2±0.3246)
(0±0235)
(0±02)
(0±02)
(3.88%) (0.6±0.4†135)
1.3±0.21
1.8±0.12,5
1.3±0.4
0.2±0.22,6
0±02,6
3:1
145
246
2,6
(0.4±0.3 )
(1.0±1.2)
(0±0 )
(0±02)
(3.26%) (0.4±0.4 )
1.3±0.3
1.6±0.31,5
1.5±0.6
0.2±0.32,6
0±02,6
2:2
(0.5±0.54)
(0.3±0.3245)
(0±02)
(0±02)
(2.65%) (0.5±0.4145)
1.5±0.22
1.5±0.6
0.6±0.46
0±02,5
0±02,5
1:3
3
235
2
(0.6±0.6 )
(0.7±0.7)
(0±0 )
(0±0 )
(0±02)
(2.04%)
1.4±0.21
1.4±0.45
0.5±0.32,6
0±02,6
0±02,6
0:4
145
3
236
2
(0.7±0.3 )
(0.2±0.2 )
(0±0 )
(0±02)
(1.43%) (0.5±0.3 )
ᶲRoot/rhizome: leaf/stem ratio. †Berberine equivalents are in parentheses. n=3.
Significant difference from spontaneous revertants (1p<0.05, 2p<0.01); from goldenseal
(3p<0.05, 4p<0.01); from presence of S9 (5p<0.05, 6p<0.01).
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3.1.6.4 Goldenseal Powder in the Presence of S9

The results of the Ames assay for GSP (lot 1044) in the presence of S9 liver
enzymes are shown in Table 7. Berberine sulfate equivalents are in parentheses for each
ratio and each goldenseal concentration. Sodium azide resulted in a fold change of
206±29.1. For GSP 4:0 with S9, fold changes ranged from 0.1±0.2 (at 2xMIC) to
1.5±0.3 (at 0.5xMIC). For this same ratio of berberine equivalents, the fold changes
ranged from 0 (at MIC and at 2xMIC) to 1.1±0.2 (at 0.25xMIC). Fold changes for GSP
3:1 with S9 ranged from 0.3±0.1 (at 2xMIC) to 2.0±0.7 (at 0.5xMIC) with fold changes
of berberine equivalents ranging from 0±0 (at 2xMIC) to 0.9 (at 0.125xMIC and
0.25xMIC). GSP 2:2 with S9 elicited fold changes between 0.9±0.4 (at 2xMIC) and
2.1±0.5 (at 0.5xMIC) with berberine fold changes from 0±0 (at 2xMIC) to 1.0 (at
0.125xMIC and 0.25xMIC). Fold changes for GSP 1:3 with S9 ranged from 0.3±0.2 (at
2xMIC) to 2.1±0.7 (at 0.25xMIC) and berberine equivalents with S9 had fold changes
from 0±0 (at 2xMIC) to 1.3±1.1 (at 0.5xMIC). GSP 0:4 in the presence of S9 resulted in
fold changes ranging 0.3±0.2 (at 2xMIC) to 2.3±0.7 (at 0.25xMIC) while its berberine
equivalents in the presence of S9 ranged 0±0 (at 2xMIC) to 1.0±0.3 (at 0.125xMIC).
Although there were some fold changes at or greater than 2, there was not an
accompanying dose response for any of the ratios; therefore, GSP in the presence of S9 is
not considered to be mutagenic. Berberine sulfate equivalents in the presence of S9 at the
concentrations tested did not result in fold changes greater than 2 with a dose response, so
are therefore considered non-mutagenic.
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Table 7. Fold Changes of GSP in the Presence of S9 Activation
R:Lᶲ
0.125xMIC
0.25xMIC
0.5xMIC
MIC
2xMIC
Ratio
1.4±0.6
1.4±0.31
1.5±0.32
0.8±0.5
0.1±0.22
4:0
3
4
2,3
(1.0±0.2†)
(1.1±0.2 )
(0.6±0.4 )
(0±0.1 )
(0±02)
(3.88%)
1.5±0.41
1.4±0.31
2.0±0.71§
1.1±0.4
0.3±0.12
3:1
4
4
4
2,4
(0.9±0.1 )
(0.9±0.2 )
(0.8±0.1 )
(0.2±0.1 )
(0±02,4)
(3.26%)
1.5±0.32
1.9±0.22
2.1±0.52§
1.7±0.51
0.9±0.4
2:2
(1.0±0.33)
(1.0±0.54)
(0.8±0.24)
(0.1±0.12,4)
(0±02,4)
(2.65%)
1.7±0.32
2.1±0.72§
2.0±0.62§
1.7±1.0
0.3±0.22
1:3
4
4
1,3
(0.9±0.3 )
(0.9±0.1 )
(1.3±1.1)
(0.4±0.5 )
(0±02,3)
(2.04%)
2.2±0.81§
2.3±0.72§
1.3±0.2
1.6±0.7
0.3±0.22
0:4
3
4
4
3
(1.0±0.3 )
(0.9±0.2 )
(0.7±0.2 )
(0.6±0.6 )
(0±02,4)
(1.43%)
ᶲRoot/rhizome: leaf/stem ratio. †Berberine equivalents are in parentheses. n=3.
§Fold change > 2.0. Significant difference from spontaneous revertants (1p<0.05,
2

p<0.01); from goldenseal (3p<0.05, 4p<0.01).

3.1.6.5 Goldenseal Solid in the Absence of S9

The results of the Ames assay for GSS (lot 1044) without S9 are shown in Table
8. Berberine sulfate equivalents are in parentheses for each ratio and each goldenseal
concentration. Sodium azide led to a fold change of 166±39.6. For GSS 4:0 in the
absence of S9, fold changes ranged from 0±0 (at 0.5xMIC, MIC, and 2xMIC) to 2.0±1.6
(at 0.25xMIC). For this same ratio of berberine equivalents, fold changes ranged from
0.1±0.1 (at 2xMIC) to 1.2±0.1 (at 0.125xMIC). Fold changes for GSS 3:1 in the absence
of S9 ranged from 0±0 (at 0.5xMIC, MIC, and 2xMIC) to 0.9±0.5 (at 0.125xMIC) with
fold changes of berberine equivalents ranging from 0.3±0.3 (at 2xMIC) to 1.0±0.1 (at
0.125xMIC and 0.5xMIC). GSS 2:2 without S9 elicited fold changes between 0±0 (at
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0.5xMIC, MIC, and 2xMIC) and 0.7±0.2 (at 0.125xMIC) with berberine fold changes
from 0±0 (at 2xMIC) to 1.1±0.3 (at 0.5xMIC). Fold changes for GSS 1:3 without S9
ranged from 0±0 (at MIC and 2xMIC) to 1.2±1.0 (at 0.125xMIC) and berberine
equivalents had fold changes from 0.4±0.2 (at 2xMIC) to 1.7±0.6 (at MIC). GSS 0:4 in
the absence of S9 resulted in fold changes ranging 0 (at MIC and 2xMIC) to 2.2±1.8 (at
0.125xMIC) while its berberine equivalents ranged 0.6±0.2 (at 2xMIC) to 2.1±1.2 (at
0.5xMIC). Based on these results, even though two concentrations of GSS in the absence
of S9 elicited fold changes of 2 or greater, there was no accompanying dose response,
therefore GSS without S9 is not considered mutagenic. Similar conclusions were drawn
for the berberine sulfate equivalents.

Table 8. Fold Changes of GSS in the Absence of S9 Activation
R:Lᶲ
0.125xMIC
0.25xMIC
0.5xMIC
MIC
2xMIC
Ratio
0.5±0.41
2.0±1.6§
0±02
0±0
0±01
4:0
(1.2±0.1†4)
(0.9±0.1)
(0.8±0.24)
(0.6±0.21,4)
(0.1±0.12)
(9.45%)
0.9±0.5
0.5±0.22
0±02
0±05
0±0
3:1
4
4
1,4
(1.0±0.1)
(0.9±0.1 )
(1.0±0.1 )
(0.4±0.1 )
(0.3±0.32)
(8.10%)
0.7±0.21,6
0.5±0.31
0±02
0±0
2:2
0±0 (0±01)
(0.9±0.2)
(0.9±0.23)
(1.1±0.34)
(0.5±0.43)
(6.75%)
1.2±1.0
0.7±0.3
0.1±0.12
0±02
0±02
1:3
3
1,4
4
(0.9±0.2)
(1.1±0.1 )
(1.6±0.5 )
(1.7±0.6 )
(0.4±0.21,4)
(5.39%)
2.2±1.8§5
0.8±0.22,6
0.4±0.41
0±0
0±0.12
0:4
1
1,4
3
4
(1.6±0.2 )
(1.5±0.2 )
(2.1±1.2§ )
(1.4±0.6 )
(0.6±0.21,4)
(4.04%)
ᶲRoot/rhizome: leaf/stem ratio. †Berberine equivalents are in parentheses. n=3.
§Fold change > 2.0. Significant difference from spontaneous revertants (1p<0.05,
2

p<0.01); from goldenseal (3p<0.05, 4p<0.01); from presence of S9 (5p<0.05, 6p<0.01).
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3.1.6.6 Goldenseal Solid in the Presence of S9

The results of the Ames assay for GSS (lot 1044) in the presence of S9 liver
enzymes are shown in Table 9. Berberine sulfate equivalents are in parentheses for each
ratio and each goldenseal concentration. Sodium azide gave a fold change of 166±39.6.
For GSS 4:0 with S9, fold changes ranged from 0.1±0.1 (at 0.5xMIC, MIC, and 2xMIC)
to 0.8±0.7 (at 0.25xMIC). For this same ratio of berberine equivalents, the fold changes
ranged from 0.6 (at 0.125xMIC and MIC) to 1.3 (at 0.25xMIC and 0.5xMIC). Fold
changes for GSS 3:1 with S9 ranged from 0±0 (at 2xMIC) to 0.8±1.2 (at 0.25xMIC) with
fold changes of berberine equivalents ranging from 0±0 (at 2xMIC) to 1.3±0.1 (at
0.25xMIC). GSS 2:2 with S9 elicited fold changes between 0±0 (at 2xMIC) and 0.4±0.5
(at MIC) with berberine fold changes from 0±0 (at 2xMIC) to 1.3 (at 0.125xMIC and
0.5xMIC). Fold changes for GSS 1:3 with S9 ranged from 0.1±0.1 (at 0.5xMIC and
2xMIC) to 1.3±1.4 (at MIC) and berberine equivalents with S9 had fold changes from 0.9
(at 0.5xMIC and MIC) to 1.6±0.2 (at 0.125xMIC). GSS 0:4 in the presence of S9
resulted in fold changes ranging 0±0 (at 2xMIC) to 0.2±0.3 (at 0.125xMIC) while its
berberine equivalents in the presence of S9 ranged 0.6±0.1 (at 0.125xMIC) to 1.0±0.3 (at
0.5xMIC). Based on these results, GSS in the presence of S9 did not lead to fold changes
greater than 2 with a dose response and therefore is not considered to be mutagenic at the
concentrations tested. Berberine sulfate equivalents in the presence of S9 similarly
resulted in no dose response and no fold changes over 2, thus are not considered
mutagenic.
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Table 9. Fold Changes of GSS in the Presence of S9 Activation
R:Lᶲ
0.125xMIC
Ratio
0.6±0.6
4:0
(0.6±0.2†)
(9.45%)
0.4±0.31
3:1
(1.2±0.24)
(8.10%)
0.1±0.12
2:2
(1.3±0.14)
(6.75%)
0.7±1.2
1:3
(1.6±0.2)
(5.39%)
0.2±0.32
0:4
(0.6±0.13)
(4.04%)
ᶲRoot/rhizome: leaf/stem ratio.

0.25xMIC

0.5xMIC

MIC

2xMIC

0.8±0.7
0.1±0.12
0.1±0.12
0.1±0.12
4
(1.3±0.2)
(1.3±0.1 )
(0.6±0.6)
(0.7±0.14)
0.8±1.2
0.1±0.12
0.2±0.12
0±0 (0±0)
4
(1.3±0.1)
(0.7±0.3 )
(0.5±0.5)
0.3±0.22
0.2±0.22
0.4±0.51
0±02
(1.1±0.34)
(1.3±0.44)
(0.4±0.5)
(0±0)
2
2
0.3±0.3
0.1±0.1
1.3±1.4
0.1±0.12
4
(1.5±0.3 )
(0.9±0.8)
(0.9±0.7)
(1.0±0.44)
0.1±0.12
0.1±0.22
0.1±0.22
0±02
4
4
3
(0.9±0.3 )
(1.0±0.3 )
(0.7±0.5 )
(0.8±0.14)
†Berberine equivalents are in parentheses. n=3.

Significant difference from spontaneous revertants (1p<0.05, 2p<0.01); from goldenseal
(3p<0.05, 4p<0.01)

3.1.6.7 Berberine

3.1.6.7.1 Berberine MIC

The MIC of berberine to TA100 cells was also determined as shown in Table 10
and was found to be 500µg/mL with and without S9 metabolic activation. This
concentration of berberine was higher than the amount of berberine present in the highest
amount of goldenseal required to reach MIC in TA100 (see Table 1 for goldenseal MICs
and corresponding content of berberine). The lowest concentration of berberine required
to reach MIC by goldenseal was 17.4µg/mL (in GSS 0:4) while the highest concentration
of berberine required to reach MIC by goldenseal was 388µg/mL (in GSP 4:0). Both of
these concentrations are lower than the berberine MIC suggesting that there are other
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components in the goldenseal that potentiate the action of berberine so that less is
required to elicit the same inhibitory effect as pure berberine against the TA100 cells.

Table 10. Berberine MIC and Ames Assay Results.
With S9

Without S9

Berberine MIC

500µg/mL

500µg/mL

Fold Change (MIC)

0±0*

0±0^

Fold Change (0.5xMIC)

0.1±0.1*

0±0^

Significant difference from spontaneous revertants (*p<0.05, ^p<0.01). n=3.

3.1.6.7.2 Berberine Ames Assay Results

Berberine at its MIC and half its MIC were tested in the Ames assay and the
results can be found in Table 10. Sodium azide led to a fold change of 18.7±4.08 with S9
and 19.1±0.43 without S9. For the berberine at MIC, the fold changes were 0±0 with and
without S9. At 0.5xMIC, berberine resulted in fold changes of 0.1±0.1 with S9 and 0±0
without S9. There was no significant difference between berberine with S9 and berberine
without S9 at either concentration.
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3.1.7 Subsequently Reproduced Goldenseal Lots

3.1.7.1 Rationale of Goldenseal 2:2

Based on other in vitro inflammatory and toxicity assays performed by other
members of the laboratory, it was determined that GSL 2:2 was the most active ratio of
goldenseal that exhibited the lowest toxicity. Therefore, since reproducibility is the
hallmark of any scientific experiment, subsequent lots of both GSL 2:2 and GSP 2:2 were
produced by Sleepy Hollow Herb Farm and provided for assays to determine if the
second production lots produced the same results as the previous batches. Table 11
shows the concentration of ethanol diluent, the dry weight, amount and percentage of
berberine in the new lots of GSL, lot 1047A and lot 1047B. Table 12 gives the
component lots of GSP 2:2 with the percentage of berberine found in the root/rhizome,
leaf/stem, and in the mixture (average of the two).

Table 11. Components of New Goldenseal Liquid Lots
EtOH

Dry weight

Berberine

Berberine

(%)

(mg/mL)

(mg/mL)

(%)

GSL 2:2, lot 1047A

60

17.6

2.96

16.82

GSL 2:2, lot 1047B

60

18.2

3.21

17.64
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Table 12. Components of New Goldenseal Powder Preparation

Berberine (%)

R/R lot 03200701

L/S lot 083009L

2:2 Mixture

3.65

1.43

2.54

3.1.7.2 Goldenseal 2:2 in the Absence and Presence of S9

These new lots of goldenseal were tested in the Ames assay and the results are in
Table 13. Lot 1047A of GSL 2:2 in the absence of S9 resulted in fold changes ranging
from 0±0 (at MIC and 2xMIC) to 1.1±0.4 (at 0.25MIC). In the presence of S9, lot 1047A
of GSL 2:2 elicited fold changes from 0±0 (at MIC and 2xMIC) to 1.4±0.2 (at
0.125xMIC). GSL 2:2 lot 1047B without S9 caused fold changes from 0±0 (at MIC) to
1.3±0.1 (at 0.125xMIC) and with S9 led to fold changes ranging from 0±0 (at MIC and
2xMIC) to 1.5±0.1 (at 0.125xMIC). The two new preparations of GSP (see Table 12)
were mixed in equal parts to perform the Ames assay. In the absence of S9, the GSP 2:2
resulted in fold changes from 0±0 (at 2xMIC) to 1.4±0.3 (at 0.125xMIC) and in the
presence of S9, the GSP 2:2 led to fold changes from 0.05±0.03 (at 2xMIC) to 1.9±0.3 (at
0.125xMIC). There was a significant difference between the absence and presence of S9
for GSL 2:2 lot 1047A at 0.125xMIC, GSL 2:2 lot 1047B at 0.5xMIC, and GSP 2:2 at
0.125xMIC. GSL 2:2 lot 1047A at 0.5xMIC and GSP 2:2 at 0.25xMIC were
significantly different in the absence and presence of S9 at these concentrations and also
significantly different from the negative control. All three preparations at MIC and
2xMIC with and without S9, GSL 2:2 lot 1047B without S9 at 0.125xMIC, GSP 2:2
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without S9 at 0.5xMIC, and GSP 2:2 with S9 at 0.125xMIC were only significantly
different from the negative control. Despite there being significant differences between
preparations and spontaneous revertants and absence and presence of S9, there were no
fold changes greater than 2 and no dose responses; therefore, similar to the first lot of
goldenseal and based on the mutagenicity criteria, these subsequently prepared lots of
goldenseal were determined to be non-mutagenic.

Table 13. Fold Changes of New Goldenseal 2:2 Lots in the Absence and Presence of S9
0.25xMIC
0.5xMIC
MIC
2xMIC
Preparation
0.125xMIC
Without
0.8±0.2a
1.1±0.4
0.3±0.1b
0±0c
0±0c
GSL
S9
2:2, lot
With
1047A
1.4±0.2
0.9±0.03
0.9±0.04
0±0c
0±0c
S9
Without
1.3±0.1c
1.1±0.2
0.4±0.3a
0±0c
0.01±0.01c
GSL
S9
2:2, lot
With
1047B
1.5±0.1
1.2±0.3
1.0±0.1
0±0c
0±0c
S9
Without
0.01±0.01c
0±0c
1.4±0.3a
0.4±0.2b
0.2±0.2c
S9
GSP
2:2
With
1.9±0.3c
1.4±0.3
1.1±0.3
0.3±0.2c
0.05±0.03c
S9
n=3. aSignificant difference (p<0.05) between absence and presence of S9 at this

concentration. bSignificant difference (p<0.05) between absence and presence of S9 at
this concentration and significant difference from cells + ethanol control.
difference (p<0.05) from cells + (ethanol) control.
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c

Significant

3.2 Development of Drug-Treated Cells

All three colon cell lines were treated with various amounts of doxorubicin over a
three-day period to assess their resistance to doxorubicin. The theory behind doing this
MTS assay was that the normal cells would succumb to the lowest concentration of
doxorubicin treatment, the HT-29 cells would also succumb to small concentrations, and
the doxorubicin-treated line would be able to survive in 0.1µg/mL and 1.0µg/mL, but
would succumb to 10µg/mL treatment. However, the cell proliferation assay shown in
Figure 2 does not depict this scheme. In the figure, cell viabilities as a percentage of
untreated controls are on the ordinate and the concentration of doxorubicin is on the
abscissa. CCD-18Co did not show a decrease in cell proliferation compared to nontreated CCD-18Co cells after 3 days in doxorubicin at any of the concentrations. This
could be an artifact of the generation time of this cell line as the action of doxorubicin is
cell cycle-dependent. After performing growth curves on this cell line, it was determined
that the generation time for CCD-18Co cells ranged between 4 and 6 days at early
passages (at later passages (P36-P37), after 13 days in culture, 77% of cells were
recovered- there was no additional growth, but actually a loss in the number of cells
recovered). Since doxorubicin acts to inhibit topoisomerase II, it is cell cycle-dependent;
thus, if the cells did not yet reach M phase and divide, they would not have been affected
by doxorubicin presence in the media. HT-29 cell viability was significantly decreased
from that of HT-29/Dox at 1 µg/mL, but these two cell lines showed similar decreases in
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cell proliferation in 10µg/mL doxorubicin as these lines have a generation time of less
than 3 days.

Cell Viability (% of Control)

Doxorubicin Treatment of Colon
Cell Lines
120
100
80

HT-29

60

CCD18-Co

40

HT-29/Dox

20
0
0.1
1
10
Concentration of Doxorubicin (ug/mL)

Figure 2. Doxorubicin Treatment of Colon Cell Lines. n=3.

HT-29/Dox cell viabilities were then assessed with the MTS assay to determine
resistance to various drugs (see Figure 3). Cell death as a percentage of untreated cell
death is represented on the ordinate and the concentration of drug administered is on the
abscissa of Figure 3. Reserpine, ethidium bromide (EtBr), and doxorubicin were tested.
HT-29/Dox cells were significantly killed only after addition of 500µg/mL Reserpine.
However, this resulted in less than 30% of cell death compared to untreated cells. The
addition of 8µg/mL EtBr and 8µg/mL doxorubicin caused significant cell death to occur:
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30% death due to EtBr and 50% death due to doxorubicin. Both of these drugs were able
to kill more than 90% of cells at 125µg/mL.

Doxorubicin-treated HT-29 Cell Resistance to Various Drugs and
Berberine
110

**

90

*
*

Cell Death (% of Control)

70

*

50

*

**

*

*

*

*
Reserpine

*

EtBr
Doxorubicin

^

*
30

10

4
-10

8

16.1

31.3

62.5

125

250

500

Concentration (ug/mL)

Figure 3. HT-29/Dox Cell Resistance to Various Drugs. n=3. Significant difference
from untreated cells (*p<0.05; ^p<0.01).

The concentration of Reserpine required to kill 50% of these HT-29/Dox cells
was greater than 500µg/mL; approximately 16µg/mL EtBr killed 50% of these cells; and
8µg/mL doxorubicin subdued 50% of these drug-treated cells. Therefore, the
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doxorubicin treatment scheme used to develop these cells seems to have been successful
in allowing these cells to resist several classes of drugs.

3.3 Antitumor Effects of GSL 2:2 on Colon Cell Lines

The anti-cancer effects of GSL 2:2 were first assessed using an MTS cell
proliferation assay. As can be seen in Figure 4, viabilities of the cell lines are depicted on
the ordinate and the concentrations of goldenseal added to the cells are on the abscissa.
Cell viabilities are shown as a percentage of the growth exhibited by non-treated cells; all
data points are the average of triplicate treatments. HT-29 and HT-29/Dox colon cancer
cells were both significantly inhibited upon addition of 400µg/mL GSL 2:2 after 72 hours
of treatment (65.8% and 54.5% of control, respectively) whereas the CCD-18Co normal
colon cells were not significantly inhibited at this concentration of GSL 2:2 (92.2% of
control). Subsequent addition of higher concentrations of GSL 2:2 to HT-29 cells
resulted in decreases in viabilities down to 12.1% of control (at 800µg/mL and
1600µg/mL). Addition of 800µg/mL, 1600µg/mL and 3200µg/mL GSL 2:2 to CCD18Co cells resulted in viabilities less than 10% of non-treated CCD-18Co cells after 72h
treatment. HT-29/Dox cells were only inhibited approximately 50% of non-treated HT29/Dox cells when up to 6400µg/mL GSL 2:2 were added for 72 hours. Equivalent
amounts of the GSL 2:2 diluent, 60% organic grain ethanol, did not result in significant
decreases in cell viabilities, although some of the higher amounts did significantly
enhance cell proliferation in comparison to non-treated cells (p<0.05), which suggests
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that the inhibition in cell proliferation seen in all three cell lines was not the result of the
components of the diluent but of the components of the goldenseal.

Effect of Goldenseal Liquid 2:2 on Cell Viabilities after 72h Treatment
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Figure 4: Effect of GSL 2:2 on Colon Cell Viabilities. n=3. Significant difference from
non-treated cells of respective cell lines (*p<0.05, ^p<0.01).
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3.4 Anti-Efflux Effects of Goldenseal Liquid 2:2 on Colon Cell Lines

3.4.1 Preliminary Study: Confirmation of Gene Presence

Prior to determining if goldenseal was able to regulate P-gp at the gene expression
level, the presence of the mdr1 gene was confirmed by performing PCR [11]. DNA was
extracted from untreated HT-29 monolayers and subjected to PCR. A 508bp amplicon
can be seen in Lane 1 of Figure 5 showing amplification of the primer-recognized region
of the mdr1 gene. Lanes 2 and 3 were negative PCR controls lacking either DNA
polymerase or DNA (Lane 2 and Lane 3, respectively). A 50bp ladder can be seen in
Lane 4 with the corresponding fragment sizes to the right of the gel. Lane 5 shows the βactin amplicon at 247bp. Lanes 6 and 7 lack bands as their reaction mixtures lacked
either DNA polymerase or DNA, respectively.
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Lane 1 Lane 2

Lane 3 Lane 4 Lane 5 Lane 6

Lane 7

Figure 5: Confirmed Presence of mdr1 and β-actin Genes in HT-29 Colon Cancer Cells.

3.4.2 Real Time RT-PCR

Following confirmation of mdr1 gene presence in the HT-29 cell line, cells were
treated with GSL 2:2 in varying amounts for up to three days to assess its effect on mdr1
gene expression. Based on the results shown in Figure 4, all cell lines were able to
survive addition of 400µg/mL GSL 2:2 for three days, so this concentration was chosen
as the maximum treatment; smaller doses of goldenseal in the amounts of 100µg/mL and
200µg/mL were also tested to see if they differentially affected gene expression.

The comparative Ct method was employed to analyze the RT-PCR results. Ct
refers to the threshold cycle where the fluorescence of the reporter crosses from linear
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into the exponential range. The numbers found in Tables 14-18 can be interpreted as
follows: for values less than 1, the treatment caused the sample to have a Ct value greater
than the β-actin reference indicating a decrease in mdr1 gene expression; values equal to
1 mean that the sample had the same Ct as the reference and thus no change in gene
expression between treatment and non-treatment; and values greater than 1 indicate the
treatment caused the sample to have a lower Ct value than the reference, meaning an
increase in mdr1 gene expression compared to untreated cells.

3.4.2.1 HT-29 Cells

As can be seen in Table 14, treatment of HT-29 cells with GSL 2:2 did not lead to
any significant changes in mdr1 gene expression. Upon 24 hours and 48 hours of
treatment with 100µg/mL GSL 2:2, there appears to be a slight decrease in gene
expression, whereas after 72 hours, the GSL 2:2 treatment appears to increase the mdr1
gene expression (however this is not a significant increase: p=0.11). The addition of
200µg/mL GSL 2:2 to HT-29 cells resulted in Ct values that increased with each day,
indicating increased mdr1 gene expression over time albeit not significantly in 72 hours
(p=0.09). This same trend can be seen with 400µg/mL GSL 2:2 treatment of HT-29 cells.
The GSL 2:2 is 60% organic grain ethanol-based and this diluent alone led to similar
trends as the GSL 2:2 treatment; no significant changes in mdr1 gene expression levels
between different concentrations of ethanol treatments or from their same-day nontreated controls were found. The minimal changes in mdr1 gene expression elicited by
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the goldenseal were not as great as those elicited by the diluent implying that there are
components within the goldenseal that essentially decrease the overall trend towards an
increase in mdr1 gene expression that may be exacerbated by diluent alone. Day 2
400µg/mL treatment was significantly different (p<0.05) from the 100µg/mL treatment
that day. The Day 3 untreated cells were significantly different from untreated cells on
Day 1 and Day 2.

Table 14: Comparative Ct Method of GSL 2:2 Treatment of HT-29 Cells
Concentration of GSL 2:2
Day

100µg/mL

200µg/mL

400µg/mL

1

0.4

2.1

1.2

2

0.3

2.9

3.0

3

5.0

6.4

4.5

n=6.

HT-29 cells were also treated with berberine to see if it was able to elicit any
changes in mdr1 gene expression. The results are in Table 15 and reflect treatment with
the amount of berberine found in the highest (400µg/mL) GSL 2:2 treatment. The first
and second day berberine treatments were not significantly different from non-treated
HT-29 cells. However, treatment with berberine for 72 hours elicited a significant
(p<0.01) increase in mdr1 gene expression compared to untreated cells which is
consistent with berberine being a substrate and possible inducer of P-gp.

55

Table 15: Comparative Ct method of Berberine Treatment of HT-29 Cells
Berberine (GSL 2:2 400µg/mL equivalent)

HT-29

Day 1

Day 2

Day 3

0.8

1.1

18.7^

n=6. Significant difference from untreated cells (^p<0.01).

3.4.2.2 CCD-18Co Cells

Treatment of the CCD-18Co normal colon cell line with GSL 2:2 (see Table 16)
elicited slightly different results than the HT-29 colon cancer line. After 24 and 48 hours
of treatment with 100µg/mL GSL 2:2, the normal cells did not show an increase or
decrease in mdr1 gene expression; however, this number did decrease slightly on Day 3
implying that perhaps after several more days in culture, the treatment might decrease
mdr1 gene expression significantly at this concentration. Treatment with 200µg/mL led
to variable results over the time of treatment; a slight decrease in mdr1 gene expression
levels can be seen on Days 1 and 3 without a change in expression level on Day 2. None
of the 100µg/mL or 200µg/mL treatments for Day 1 or Day 2 led to significant changes
in mdr1 gene expression level in these normal colon cells. However, there were
significant increases in mdr1 gene expression levels (p<0.01 on Days 1 and 2 and p<0.05
on Day 3) upon treatment with 400µg/mL GSL 2:2 all three days tested with greater
increases seen in subsequent days. The organic grain ethanol diluent did not result in
significant changes in mdr1 gene expression levels, although the numbers did increase
with each day.
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On Day 1, the 400µg/mL GSL 2:2 treatment was significantly different (p<0.05)
from untreated, 100µg/mL GSL 2:2 and 200µg/mL GSL 2:2 treatments that day but not
from ethanol treated cells. The Day 2 400µg/mL GSL 2:2 treatment was significantly
different from untreated, 100µg/mL GSL 2:2 and 200µg/mL GSL 2:2 but not from
ethanol treated cells that day. On Day 3, the 400µg/mL GSL 2:2 treatment was
significantly different from the untreated cells on that day. Day 2 and Day 3 treatments
were significantly different from respective treatments on Day 1. The 400µg/mL GSL
2:2 treatment was the only treatment that significantly differed between Day 2 and Day 3.

Table 16: Comparative Ct Method of GSL 2:2 Treatment of CCD-18Co Cells
Concentration of GSL 2:2
Day

100µg/mL

200µg/mL

400µg/mL

1

1.0

0.6

3.9^

2

1.1

1.0

4.2^

3

0.7

0.5

9.2*

n=6. Significant difference from same-day non-treated cells (*p<0.05, ^p<0.01).

3.4.2.3 Doxorubicin-Treated HT-29 Cells

Results of GSL 2:2 addition to HT-29/Dox cells can be seen in Table 17. As with
the HT-29 cells, there were no significant changes in mdr1 gene expression elicited by
GSL 2:2 treatment in these cells compared to non-treated cells. The trend seen upon GSL
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2:2 addition at 100µg/mL over the three days is towards a decrease in mdr1 gene
expression. Addition of 200µg/mL GSL 2:2 to HT-29/Dox cells led to no change in
mdr1 gene expression after one day, a slight increase on Day 2, and a slight decrease on
Day 3. Treatment with 400µg/mL GSL 2:2 showed a trend toward decreasing the level
of mdr1 gene expression over time. Organic grain ethanol also did not significantly alter
mdr1 gene expression in these cells compared to non-treated cells. There were no
significant differences among or between the respective treatments over time. Also,
while the organic grain ethanol treatment on Day 3 was not significantly different from
the untreated cells, it was significantly different from the other treatments that day
(p<0.05 for 100µg/mL, p<0.01 for 200µg/mL and 400µg/mL).

Table 17: Comparative Ct Method of GSL 2:2 Treatment of HT-29/Dox Cells.
Concentration of GSL 2:2
Day

100µg/mL

200µg/mL

400µg/mL

1

1.5

1.0

0.7

2

1.1

1.3

0.5

3

0.3

0.5

0.4

n=6.
As can be seen in Table 18, HT-29/Dox cells were also treated with berberine.
Berberine was administered at the equivalent amount found in the highest (400µg/mL)
treatment of GSL 2:2. Although treatment with berberine did not result in significant
changes in mdr1 gene expression, the numbers were all less than 1 suggesting a slight
trend towards a decrease in mdr1 gene expression.
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Table 18: Comparative Ct Method of Berberine Treatment of HT-29/Dox Cells
Berberine (GSL 2:2 400µg/mL equivalent)

HT-29/Dox

Day 1

Day 2

Day 3

0.5

0.5

0.5

n=6.

3.5 Effect of GSL 2:2 on P-Glycoprotein Protein Function

3.5.1 Preliminary Study

HT-29 and HT-29/Dox cells were stained with UIC2, a monoclonal antibody
(mAb) that recognizes a conformational extracellular epitope specific to P-gp. Staining
was done after cells were treated in the presence or absence of a P-gp substrate
(vinblastine, Vlb) as staining in the presence of substrate alters the conformation of the Pgp molecule to increase binding of the antibody. Results of the optimization of this assay
using HT-29 cells can be seen in Figures 6-8 as cellular micrographs depicting
fluorescence. Micrographs of unstained HT-29 cells can be seen in Figure 6, HT-29 cells
stained with UIC2 are in Figure 7 and HT-29 cells treated with Vlb and stained with
UIC2 are in Figure 8. There is slight increase in fluorescence between unstained cells
(Figure 6) and cells stained with UIC2 (Figure 7); however, there is a definite increase in
fluorescence between cells stained with antibody in the absence (Figure 7) and presence
(Figure 8) of substrate. As these staining conditions led to visual differences between the
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treatments, this effect was then measured quantitatively by performing fluorescence
spectrophotometry.

50µm

Figure 6: Unstained HT-29 Cells.

50µm

Figure 7. HT-29 Cells Stained with UIC2.

50µm

Figure 8. Vinblastine-treated HT-29 Cells Stained with UIC2.

60

3.5.2 GSL 2:2 Effect on P-gp Function in HT-29 Cells

Changes in the fluorescence of Vlb-treated UIC2-stained cells indicate an
alteration in function of the P-gp protein. GSL 2:2 treatment of HT-29 cells and its effect
on P-gp function can be seen in Figure 9 with relative fluorescence units (RFU) on the
ordinate and treatments on the abscissa. Cells treated with Vlb then stained with UIC2
exhibited greater fluorescence than cells stained with UIC2 (in the absence of substrate),
though this increase was not significant. Cells treated with substrate and 100µg/mL GSL
2:2 showed a significant decrease (p<0.05) in fluorescence compared to controls
indicating a decrease in function of the P-gp protein in these cells. Treatment with
200µg/mL GSL 2:2 and Vlb did not result in a change in fluorescence; however,
treatment with Vlb and 400µg/mL GSL 2:2 showed a significant decrease (p<0.05) in
fluorescence, indicating decreased binding of the UIC2 mAb and thus a decreased
function of P-gp.
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GSL 2:2 Effect on P-gp Function in HT-29 Cells
1.6
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Treatment

Figure 9. GSL 2:2 Effect on P-gp Function in HT-29 Cells. n=3. Significant difference
from untreated cells (*p<0.05). RFU represents relative fluorescence units.

3.5.3 GSL 2:2 Effect on P-gp Function in HT-29/Dox Cells

Vlb-treated HT-29/Dox cells stained with UIC2 exhibited a significant increase in
fluorescence (p<0.05) over UIC2-stained untreated cells (see Figure 10). Treatment of
cells with Vlb and 100µg/mL and 200µg/mL GSL 2:2 did not significantly alter the
fluorescence of these cells; however, treatment with Vlb and 400µg/mL GSL 2:2 did
significantly reduce fluorescence (p<0.01), which suggests a decrease in P-gp protein
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function. The trend seen with the decrease in fluorescence also suggests that higher
concentrations of GSL 2:2 would continue to decrease the function of the P-gp protein.

GSL 2:2 Effect on P-gp Function in Doxorubicin-Treated HT-29 Cells
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Cells + UIC2 + Vlb + GS400

Treatment

Figure 10. GSL 2:2 Effect on P-gp Function in HT-29/Dox Cells. n=3. Significant
difference from untreated cells (*p<0.05, ^p<0.01). RFU represents relative fluorescence
units.
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3.6 Potentiation of a Known Chemotherapeutic Drug by GSL 2:2

3.6.1 Effect of Vinblastine on Colon Cell Viabilities

In order to determine if GSL 2:2 has the capability of potentiating the action of a
known chemotherapeutic drug, the effects of that drug alone were assessed in the cell
lines used in the assay. Therefore, the effect of the addition of vinblastine (Vlb), a
common in vitro anti-cancer drug, was determined by MTS assay. The results are in
Figure 11 with cell viability as a percentage of non-treated cells on the ordinate and Vlb
treatment on the abscissa. In HT-29 colon cancer cells, the addition of 0.5µg/mL Vlb
was able to reduce cell viabilities by 50%, 5.0µg/mL Vlb decreased cell viabilities 65%,
and 50µg/mL Vlb reduced HT-29 viabilities 90% compared to untreated HT-29 cells. In
CCD-18Co cells, 20µg/mL Vlb was able to reduce viabilities 25% compared to untreated
CCD-18Co cells and 50µg/mL Vlb was able to reduce cell viabilities 80%. In HT29/Dox cells, 20µg/mL of Vlb reduced cell viability 20% whereas 50µg/mL Vlb reduced
viabilities 60% in these cells. Therefore, a reduction of 50% in HT-29 cells by 0.5ug/mL
Vlb and a reduction of 60% in HT-29/Dox cells by 50µg/mL Vlb indicate that the HT29/Dox cells require approximately 100 times the concentration of Vlb to reach the same
amount of cell death as in HT-29 cells.
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Effect of Vinblastine on Cell Proliferation of Colon Cell Lines
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Figure 11. Effect of Increasing Concentrations of Vinblastine on the Viabilities of Three
Colon Cell Lines. n=3. Significant difference from untreated cells (*p<0.05, ^p<0.01).

3.6.2 Potentiation in HT-29 Colon Cancer Cells

Potentiation of a known chemotherapeutic was assayed utilizing an MTS assay.
Figure 12 shows the results of HT-29 cells incubated with Vlb, Vlb and GSL 2:2, Vlb and
berberine, or with media. Cell death as a percentage of cells treated with Vlb alone is on
the ordinate and the concentration of GSL 2:2 (or berberine equivalent) added to the cells
and Vlb is on the abscissa. In HT-29 cells, 0.5µg/mL of Vlb was able to cause 11.2% cell
death compared to untreated HT-29 cells (see Figure 12). Upon the addition of 50µg/mL
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or more of GSL 2:2, the viability of the cells decreased in a dose dependent manner,
significantly so with 300µg/mL, 400µg/mL and 500µg/mL GSL 2:2 in the presence of
0.5µg/mL Vlb. Equivalent doses of berberine were also tested to see if any effect brought
about by the GSL 2:2 could solely be attributed to its berberine constituent alone. The
percentage of berberine in this GSL 2:2 preparation was 16.82%. Only at the highest
concentration tested (84.1µg/mL; 16.82% of 500µg/mL) was berberine able to increase
significantly the death of HT-29 cells over cells treated with Vlb alone. At 200µg/mL,
300µg/mL and 400µg/mL, the effects of Vlb + GSL 2:2 were significantly different from
Vlb + berberine (p<0.05) with potentiation by GSL 2:2 significantly greater than
potentiation by berberine.
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HT-29 Cell Death in the Presence of Vinblastine (0.5ug/mL)
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Figure 12. Potentiation of Vinblastine by GSL 2:2 and Berberine in HT-29. n=3.
Significant difference from cells + vinblastine (*p<0.05; ^p<0.01). Brackets indicate
significant difference (p<0.05) between goldenseal and berberine.

Table 19 shows the amount of cell death caused by GSL 2:2 alone (“GSL 2:2”
column) and in combination with 0.5µg/mL Vlb (the fourth column). The third column,
“Calculated Difference” reflects the additive death of GSL 2:2 and Vlb; this number was
calculated by adding death caused by GSL 2:2 alone (second column) to that of death
caused by Vlb alone (11.2%). The actual death caused by Vlb + GSL 2:2 (fourth
column) was determined experimentally. The amount of additional death over that of
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what was additively calculated is reflected in the last column. Each concentration of
GSL 2:2 led to potentiation of the Vlb from 19.6% up to 47.9%.

Table 19: Potentiation by GSL 2:2 in HT-29 Cells
HT-29 Cell Death
Concentration
of GSL
(µg/mL)
0
25
50
100
200
300
400
500

GSL 2:2

Calculated
Difference

0.5µg/mL Vlb
+ GSL 2:2

0
-2
-5
-12.4
8.1
24
34.2
45

11.2
9.2
6.2
-1.2
19.3
35.2
45.4
56.2

11.2
41.8
25.8
34.1
46.2
69.2
93.3
99.8

Actual Calculated =
Additional
Death
0
32.6
19.6
35.3
26.9
34
47.9
43.6

3.6.3 Potentiation in CCD-18Co Normal Colon Cells

In Figure 13, CCD-18Co cell death as a percentage of cells treated with Vlb alone
is on the ordinate and the concentration of GSL 2:2 (or berberine equivalent) added to the
cells and Vlb is on the abscissa. As can be seen in Figure 13, 20µg/mL Vlb was able to
cause 65.7% cell death in CCD-18Co normal colon cells. GSL 2:2 caused cell death in
the presence of 20µg/mL Vlb in a dose-dependent manner. Lower dosages of GSL 2:2
(25µg/mL and 50µg/mL) when added to Vlb were able to decrease cell death
significantly. Increased doses of GSL 2:2 (400µg/mL and 500µg/mL) in the presence of
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Vlb were able to increase cell death significantly compared to cells treated only with Vlb.
Similar trends were seen with berberine equivalents. At 300µg/mL, the effects of Vlb +
GSL 2:2 and Vlb + berberine were significantly different from each other but not from
the control (cells treated with Vlb alone).

CCD-18Co Cell Death in the Presence of Vinblastine (20ug/mL)
120

*

100

**

**

Cell Death (% of Control)

80

60
Goldenseal
Berberine

*
40

^

*

20

*

*
*

0
0

25

50

100

200

300

400

500

Goldenseal, ug/mL (Berberine Equivalent, 16.82%)

Figure 13. Potentiation of Vinblastine by GSL 2:2 and Berberine in CCD-18Co Cells.
n=3. Significant difference from cells + vinblastine (*p<0.05; ^p<0.01). Brackets
indicate significant difference (p<0.05) between goldenseal and berberine.

Table 20 shows the amount of cell death caused by GSL 2:2 alone (“GSL 2:2”
column) and in combination with 20µg/mL Vlb (fourth column) in CCD-18Co normal
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colon cells. The third column, “Calculated Difference” reflects the additive death of GSL
2:2 and Vlb; this number was calculated by adding death caused by GSL 2:2 alone
(second column) to that of death caused by Vlb alone (65.7%). The actual death caused
by GSL 2:2 and Vlb (fourth column) was determined experimentally. The amount of
additional death over that of what was additively calculated is reflected in the last
column. Lower concentrations of GSL 2:2 alone actually led to increased cell viability
over that caused by incubating the CCD-18Co cells with Vlb alone. Concentrations of
300µg/mL GSL 2:2 and above led to slight additional cell death over Vlb alone.

Table 20. Potentiation by GSL 2:2 in CCD-18Co Cells.
Cell Death
Concentration
of GSL
(µg/mL)

GSL 2:2

Calculated
Difference

20µg/mL Vlb +
GSL 2:2

0
25
50
100
200
300
400
500

0
-1
-2.5
-5.6
-1.4
3
7.8
27.5

65.7
64.7
63.2
60.1
64.3
68.7
73.5
93.2

65.7
18.9
26
44.8
57.6
76.7
86.3
93.5
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Actual Calculated =
Additional
Death
0
-45.8
-37.2
-15.3
-6.7
8
12.8
0.3

3.6.4 Potentiation in Doxorubicin-treated HT-29 Colon Cancer Cells

In Figure 14, HT-29/Dox cell death as a percentage of cells treated with Vlb alone
is on the ordinate and the concentration of GSL 2:2 (or berberine equivalent) added to the
cells and Vlb is on the abscissa. The addition of 20µg/mL Vlb to HT-29/Dox cells led to
a decrease in cell viability by 24% (see Figure 14). Addition of GSL 2:2 to 20µg/mL Vlb
increased cell deaths in a dose-dependent manner above this 24%, significantly so in
concentrations 300µg/mL GSL 2:2 and above. Berberine equivalents were likewise able
to increase cell death in the presence of 20µg/mL Vlb significantly so at dose equivalents
400µg/mL and greater. Differences between goldenseal and berberine were only
significant at 750µg/mL.
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HT-29/Dox Cell Death in the Presence of Vinblastine (20ug/mL)
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Figure 14: Potentiation of Vinblastine by GSL 2:2 and Berberine in HT-29/Dox Cells.
n=3. Significant difference from cells + vinblastine (*p<0.05; ^p<0.01). Brackets
indicate significant difference (p<0.05) between goldenseal and berberine.

Table 21 shows the amount of cell death caused by GSL 2:2 alone (“GSL 2:2”
column) and in combination with 20µg/mL Vlb (fourth column) in doxorubicin-treated
HT-29 cells. The third column, “Calculated Difference” reflects the additive death of
GSL 2:2 and Vlb; this number was calculated by adding death caused by GSL 2:2 alone
(second column) to that of death caused by Vlb alone (24%). The actual death caused by
GSL 2:2 and Vlb (fourth column) was determined experimentally. The amount of
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additional death over that of what was additively calculated is reflected in the last
column. All concentrations of GSL 2:2 were able to potentiate the action of Vlb in HT29/Dox cells causing 23.9% to 57.2% additional cell death over cells treated with Vlb
alone.

Table 21: Potentiation by GSL 2:2 in HT-29/Dox Cells.
Cell Death
Concentration
of GSL
(µg/mL)
0
25
50
100
200
300
400
500

GSL 2:2

Calculated
Difference

20µg/mL Vlb +
GSL 2:2

0
-1.5
-2.5
-6.4
3.8
25
45.5
45.5

24
22.5
21.5
17.6
27.8
49
69.5
69.5

24
46.4
58.2
72.1
85
95.8
99
98.7

Actual Calculated =
Additional
Death
0
23.9
36.7
54.5
57.2
46.8
29.5
29.2

Table 22 shows the amount of cell death caused by berberine alone (“Bbr”
column) and in combination with 20µg/mL Vlb (fourth column) in HT-29/Dox cells. The
third column, “Calculated Difference” reflects the additive death of berberine and Vlb,
calculated by adding death caused by berberine alone (second column) to that of death
caused by Vlb alone (24%). The actual death caused by berberine and Vlb (fourth
column) was determined experimentally. The amount of additional death over that of
what was additively calculated is reflected in the last column. All concentrations of
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berberine were able to potentiate the action of Vlb in HT-29/Dox cells causing 4.1% to
49.5% additional cell death over cells treated with Vlb alone. However, when compared
to GSL 2:2 potentiation in these cells, at lower concentrations (100µg/mL, 200µg/mL,
and 300µg/mL GSL 2:2 concentrations), the additional cell death caused by GSL 2:2 was
substantially higher than that caused by berberine: 54.5%, 57.2%, and 46.8% by GSL 2:2
versus 17.5%, 6.9%, and 4.1% by berberine, respectively. At 400µg/mL and 500µg/mL
GSL 2:2 concentrations or berberine equivalents, the amount of additional death caused
by both were approximately the same: 29.5% and 29.2% for GSL 2:2 and 25.9% and
36.2% for berberine respectively.

Table 22: Potentiation by Berberine in HT-29/Dox Cells
Cell Death
GSL 2:2
Concentration
0
100
200
300
400
500
750
1000

Berberine
Equivalent
Concentration
0
16.8
33.6
50.5
67.3
84.1
126.2
168.2

Bbr

Calculated
Difference

20µg/mL
Vlb + Bbr

0
9
15
27
33
33.5
26
32

24
33
39
51
57
57.5
50
56

24
50.5
45.9
55.1
82.9
93.7
99.5
98.8
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Actual –
Calculated =
Additional Death
0
17.5
6.9
4.1
25.9
36.2
49.5
42.8

3.7 The Effect of GSL 2:2 on Cellular Attachment

GSL 2:2 was also tested for its ability to affect colon cellular attachment in vitro
to determine if goldenseal might have an impact on cells leaving the primary colon
malignancy to metastasize to secondary sites within the body. Cells were seeded,
allowed to attach overnight (“Attached”), and treated with GSL 2:2 or treated with GSL
2:2 during cell seeding (“Not Attached”). Cell death as a percentage of untreated cells is
on the ordinate and concentration of GSL 2:2 is on the abscissa of Figures 15-17.

3.7.1 HT-29 Cell Attachment

In HT-29 cells (see Figure 15), there was more significant death of attached cells
over cells not attached when treated with 12.5ug/mL, 50µg/mL, and 1250µg/mL GSL
2:2. However, there was significant advantage of attached cell survivability when
treated with 6.3µg/mL, 100µg/mL, 200µg/mL, and 300µg/mL GSL 2:2 which suggests
that certain concentrations of GSL 2:2 may actually aid in prevention of attachment of
secondary metastases.
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The Effect of Goldenseal Liquid 2:2 on HT-29 Cell Attachment
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Figure 15: Cellular Attachment in HT-29 Colon Cancer Cells. n=3. Significant
difference from untreated cells (*p<0.05, ^p<0.01). Brackets indicate significant
difference (p<0.05) between attached and not attached.

3.7.2 CCD-18Co Cell Attachment

In CCD-18Co cells (Figure 16), attached cells exhibited significantly less cellular
death than non-attached cells when treated with 100µg/mL and 300µg/mL GSL 2:2 with
the reverse occurring at 600µg/mL.
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The Effect of Goldenseal Liquid 2:2 on CCD-18Co Cell Attachment
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Figure 16: Cellular Attachment in CCD-18Co Normal Colon Cells. n=3. Significant
difference from untreated cells (*p<0.05, ^p<0.01). Brackets indicate significant
difference (p<0.05) between attached and not attached.

3.7.3 HT-29/Dox Cell Attachment

In HT-29/Dox cells (Figure 17), there was a significant disadvantage to nonattached cells that were treated with 50µg/mL, 600µg/mL, 2500µg/mL, and 10,000µg/mL
GSL 2:2 which, like cellular attachment in HT-29 cells, suggests that goldenseal has an
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effect on the ability of HT-29/Dox cells to attach when treated with various
concentrations of goldenseal.

The Effect of Goldenseal Liquid 2:2 on Doxorubicin-treated
HT-29 Cell Attachment
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Figure 17: Cellular Attachment in HT-29/Dox Colon Cancer Cells. n=3. Significant
difference from untreated cells (*p<0.05, ^p<0.01). Brackets indicate significant
difference (p<0.05) between attached and not attached.
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CHAPTER FOUR
DISCUSSION

4.1 Ames Assay

The standard plate incorporation assay was chosen over the pre-incubation
technique because the latter resulted in killing of the TA100 cells. “Pre-incubation”
required that the entire concentration of goldenseal (without and with S9) be incubated
with TA100 cells for 30 minutes in a volume smaller than 1mL. The concentration of
goldenseal in this volume was above the MIC of the TA100 cells and mostly resulted in
zero colonies on all of the test and positive control plates. A mammalian lymphoma
mutagenicity assay was not considered due to issues regarding pH and osmolality
changes; additionally, Li et al found that the mouse lymphoma mutagenicity assay and
the Ames mutagenicity assay gave similar results [86]. As there is approximately an 8090% correlation between agents causing mutation in the Ames assay also being
carcinogenic in humans, the results of this study suggest that the ratios, preparations, and
concentrations of goldenseal tested were not mutagenic.

The mutagenicity of goldenseal was compared to one of its major alkaloids,
berberine, to see if there were any differences in mutagenic potential. Nozaka and
colleagues found berberine hydrochloride to be non-mutagenic, yet Zuo et al. suggested
that this may be due to “significant biotransformation [of the compounds] rather than
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poor aqueous solubility,” as they found that certain moieties were retained and other
oxidation products were found [87, 88]. However, using this in vitro assay, the results of
this study with berberine sulfate corroborate the findings of Nozaka’s group.

Drugs taken orally must cross the intestinal epithelium; the presence of P-gp in
this epithelium leads to efflux of these ingested drugs often leading to reduced
bioavailability. Low (oral) bioavailability could be problematic as therapeutic levels of
the drug may not be reached in the plasma or it may lead to variable uptake of the drugnot a constant dosing of the drug. If the drug has a narrow therapeutic range, this
invariable dosing could also be problematic [22]. The mutagenicity of goldenseal was
tested to assay the feasibility of safely administering goldenseal clinically.
Chemotherapy causes nausea, hair loss, and other undesirable side effects but when
combined with goldenseal it has the potential to block P-gp-mediated efflux of the
chemotherapeutic from cancer cells and potentiate the action of the chemotherapeutic.
This could lead to lower amounts of medication used to reach a satisfactory intracellular
drug level (increased therapeutic index) with less severe side effects and treatment
success. As the results of this study and others suggest that GSL 2:2 is the most active
form and ratio exhibiting the least toxicity, the possibility of oral administration is still
well within the bounds of possibility. A Helicobacter pylori study performed by another
member of the laboratory suggested that goldenseal is stable at pH values found in the
stomach and thus would not be destroyed by a trip through the digestive system and be
able to exert its effects in the colon (unpublished data).
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4.2 Development of Drug-Treated Cells

Kudoh and colleagues used doxorubicin to transiently treat or select MCF-7
breast cancer cells for resistance. Using DNA microarray, they found induction of gene
expression of a wide variety of cell cycle, signal transduction, transcription factor, and
metabolic genes beginning 3 hours after doxorubicin treatment and continuing to increase
up to 15 hours. When gene repression occurred, it happened rapidly within an hour after
doxorubicin treatment and reached almost complete suppression after nearly five hours
[89]. Therefore, Kudoh’s study suggested that any changes occurring in doxorubicintreated cells would occur relatively quickly. However, doxorubicin has been found to
downregulate the activity of DNMT1 which re-methylates DNA, so without the activity
of this enzyme methylating the mdr1 promoter, the gene is no longer repressed through
this mechanism [90]. Hence, doxorubicin could be acting through several mechanisms,
not all of which are cell cycle-dependent.

Kim et al. reported that the IC50 value of doxorubicin was higher in a
hepatocarcinoma cell line with moderate mdr1 expression (Hep3b) than one with high
mdr1 expression (HepG2), similar to what was found in these colon cell lines [91]. It is
unclear if these effects could be solely due to the generation times of the cell lines.
Dalton and colleagues found a close correlation between cellular resistance to
doxorubicin and P-gp amount in a human myeloma cell line [92]. This further goes to
show that there doesn’t appear to be single correlations with respect to doxorubicin
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resistance across different types of carcinomas and that there may be redundant
mechanisms leading to a MDR outcome.

4.3 Gene Expression

GSL 2:2 at 400µg/mL led to significant increases in mdr1 gene expression in
CCD-18Co normal colon cells after 24, 48, and 72 hours. GSL 2:2 did not significantly
alter mdr1 gene expression levels in HT-29 colon cancer cells or in HT-29/Dox cells.
Taken together, if GSL 2:2 was taken concomitantly with a chemotherapeutic, this data
suggests that the goldenseal might offer something of a protective effect to the normal
colon cells, shielding them from the powerful effects of the administered
chemotherapeutic if goldenseal confers the normal cells the ability to increase P-gpmediated efflux while potentiating the action of the administered drug leading to the
death of the colon cancer cells.

Treatment with berberine did not lead to any significant changes in mdr1 gene
expression in the HT-29/Dox cells; however, at the highest concentration tested (in the
400µg/mL GSL 2:2 equivalent berberine amount), berberine led to a significant increase
in mdr1 gene expression in HT-29 cells after 72 hours of treatment. Since 400µg/mL of
GSL 2:2 did not cause a significant increase in mdr1 gene expression in HT-29 cells after
72 hours, this suggests that there are other components in the goldenseal that block this
upregulation caused by the pure berberine treatment.
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mdr1 expression can be upregulated by increasing the amount of mdr1 message
via mRNA stabilization or through promoter activation [13]. Stabilization of mRNA
which increases its half-life has been shown in H9 cells (an increase from 30 minutes to 6
hours) and in rat mdr1b hepatocytes (an increase from 30 minutes to 16 hours); this effect
may be accomplished through MAPKs like ERK and JNK, IL-8, and/or NFκB [51]. The
mdr1 mRNA is regulated by several cellular stress responses induced by environmental
stressors or toxicants. The mdr1 gene promoter shares homology to many other
eukaryotic promoters as “redundancy of signal transduction and transcriptional
mechanisms is the basis for the virtually ubiquitous inducibility of the mdr1 gene” [93].
If goldenseal acts on this common promoter, detecting specific effects on mdr1 could
prove difficult to define specifically amidst the effects of other induced genes. Johnstone
et al. suggested that mdr1 plays an important role in differentiation and escape from
caspase-dependent cellular apoptosis and this may ultimately be due to the complexity of
the interaction between the elements acting on the homologous mdr1 promoter [12, 94].

Kim et al. [91] reported that “there was no apparent relationship between the level
of mdr1 expression and Adriamycin [doxorubicin] sensitivity,” at least in hepatocellular
carcinoma lines which corroborates the data in this study. There are other mechanisms
that can account for doxorubicin sensitivity in the absence of a change in mdr1 gene
expression- other efflux (or influx) proteins, alterations to these proteins, induction of
signal transduction pathways, protein stability, or a variety of other cellular processes
could be involved, even in the absence of the involvement of P-gp.
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Goldstein reported a correlation between mdr1 gene expression and prognosis in
leukemia and lymphoma” [95]. However, there does not seem to be an association
between mdr1 gene expression and in vitro resistance in this solid tumor line; therefore,
this suggests that the mdr1 gene might not serve as an appropriate biomarker for the
etiology and progression of this cancer in vivo.

Although Taylor and Heasman reported in 1994 that β-actin expression can be
variable and can decrease in drug-resistant cells, visual inspection of amplicons run on
agarose gels did not suggest this occurred in the HT-29/Dox cells (data not shown) [96].

4.4 P-gp Function

GSL 2:2 caused a significant reduction in P-gp protein function in HT-29 cells
when added at concentrations of 100µg/mL and 400µg/mL and in HT-29/Dox cells when
added at 400µg/mL. Therefore, goldenseal appears to act not at the gene expression level
but at the protein function level. Chin-Yee and colleagues noted that “increased
expression of P-gp in tumors is not always characterized by DNA or RNA amplification”
which may also extend to non-correlation with protein function [20]. Other natural
compounds such as capsaicin and the major metabolite of curcumin, tetrahydrocurcumin,
are similarly able to modulate the functional efflux of P-gp [97, 98].
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A phycoerythrin (PE)-conjugated mAb was utilized in this assay (as opposed to a
FITC-conjugated mAb) as direct conjugation to PE was found to have “much higher
quantum efficiency” and permit “more reliable detection of low but significant levels of
P-gp expression” [55]. Additionally, cells normally autofluoresce in the FITC (bluegreen) range which would interfere with true measurement of FITC-conjugated antibody
fluorescence [99]. The UIC2 mAb was chosen over other antibodies such as MRK16 and
4E3 as their epitopes have been shown to be occluded totally or partially under certain
conditions leading to poor binding of the mAbs to cells [20].

4.5 Potentiation by Goldenseal

GSL 2:2 was able to potentiate the action of Vlb in HT-29 and HT-29/Dox cells,
though not in CCD-18Co normal colon cells. Microbial MDR efflux pump inhibitors
naturally synthesized by plants have previously “been used to increase the efficacy of
plant antimicrobials up to 2000-fold” [48]. Stermitz and colleagues also found synergy
among components of another plant used medicinally [67]. Since GSL 2:2 was able to
potentiate Vlb, a common chemotherapeutic, it is plausible that it would also be able to
potentiate other drugs as well. The results of this potentiation assay suggest that if
administered in conjunction with a known chemotherapeutic in a clinical situation,
ultimately lower doses of the drug could be administered to gain the same outcome as if
the drug was administered at higher doses in the absence of GSL 2:2.

85

4.6 Goldenseal

Goldenseal has been shown to have antimicrobial effectiveness against intestinal
protozoa such as Entamoeba histolytica, Trichomonas, and Giardia lamblia in addition to
Salmonella, Shigella, Klebsiella, Escherichia, Proteus, Staphylococcus, Leishmania, and
Vibrio [100, 101]. Since GSL 2:2 was able to decrease P-gp protein function in colon
cancer cell lines, if the same effect translates to in vivo clinical colon cancers leading to a
decrease in P-gp function, this could lead to an increase in the availability of orallyadministered drugs with the added benefit of GSL conferring anti-intestinal pathogen
effects as well. IV-administration of goldenseal would be unnecessary as previous
studies have found goldenseal to be stable at low pH (such as that found in the stomach),
which would circumvent problems associated with aichmophobia, indwelling catheters,
or other issues and help aid patient compliance.

Goldenseal and its components berberine and hydrastine are well-known
inhibitors of the cytochrome P450 enzyme Cyp3A4 in vitro [102]. Goldenseal has also
been shown to inhibit Cyp2C8 and Cyp2D6, two other P450 isoforms [103, 104]. These
enzymes are a group of heme-containing mono-oxygenases found in the small intestine,
liver, and other tissues that detoxify and bioactivate xenobiotics. Cyp3A4 metabolizes
nearly 50% of the prescription drugs consumed by humans (Cyp2D6 also metabolizes
prescription drugs, but not to this extent) [62]. Downregulation of these enzymes has
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been circumvented in vivo by closely monitoring consumption of goldenseal so as not to
lead to patient drug toxicity from accumulation of non-metabolized prescription drugs.

Goldenseal has been shown to be poorly absorbed when given orally [100]. This
phenomenon could be circumvented by conjugation with a drug carrier (such as a lipid
excipient like Peceol ® or Gelucire®) that has been shown to reduce P-gp efflux in liver,
spleen, lung, and bone to deliver the drug wholly to the intestines to increase the
bioavailability of these conjugated-orally-administered drugs [100, 105]. There is also
the possibility of administering a liquid GSL 2:2 extract-filled enteric-coated tablet so
coated to block absorption until it reaches the intestine [100].
The standardization of goldenseal is only a small part of the whole step towards
ensuring proper product component reporting. The part of the plant used, where it was
harvested, the availability of nutrients, growing/harvesting conditions, formulation and
other factors all influence the proportions of component molecules in the plant
(phytochemical differences). Currently price seems to be the only way to ensure that
what is purchased is anywhere close to the benchmark recommended daily dosage for
many NHP including goldenseal [106].
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CHAPTER FIVE
FUTURE RECOMMENDATIONS

GSL 2:2 was found to have an effect on P-gp protein function but not on mdr1
gene expression. Analyses of the effect of GSL 2:2 on P-gp protein expression through
Western blot or similar expression assays would be a good supplement to this study.
Potentiation studies with other classes of chemotherapeutics would also be useful to see if
GSL 2:2 is able to potentiate the action of a wide variety of drugs or only the action of
indole alkaloids.

Since GSL 2:2 is a combination of leaf/stem and root/rhizome preparations of the
goldenseal plant, a Limulus assay to rule out contributions by gram-negative bacterial
endotoxins should be performed. Roots/rhizomes are not treated with an antimicrobial
before processing, therefore it is possible that the lipopolysaccharides of bacteria attached
to these sections of the plants could be partially contributing to the effects seen in these in
vitro assays, if only by a small percentage. It would be a good idea to know if this is
actually occurring and to what extent or if this involvement is absent.

Since goldenseal has been reported to block the effects of the P450 isoform
Cyp3A4, other isoforms of the P450 family and other drug-metabolizing cytochromedependent mono-oxygenases, cytochrome-independent oxidases, amidases, esterases,
glutathione s-transferases, sulfo-transferases, acyl and methyl transferases,
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dehydrogenases, and peroxidases may be analyzed to see if these highly expressed drug
metabolizing enzymes are effected by GSL 2:2.

Although there were no significant changes in mdr1 gene expression in the colon
cancer cells or in the drug-treated colon cancer cells, mRNA expression levels do not
always correlate with changes in protein levels or protein function, as seen here. Other
issues with mRNA stability, interaction with other biomolecules (such as chaperone
proteins), or issues with protein targeting to the plasma membrane could account for the
decrease in cellular viability upon addition of goldenseal (see Figure 4). For instance, in
HT-29/Dox cells, the activity and mRNA and protein expression of a Na+/H+ exchanger
were increased over that in regular HT-29 cells which may or may not have led to the
alkalinization of the cytoplasm in the drug-treated cells [107]. Doxorubicin is a weak
base and in an acidic environment can be protonated, thus sequestering it in the
cytoplasm rendering it unable to permeate membranes. The alkaline nature of the drugtreated (MDR cells) probably led to the prevention of the inactivation of the doxorubicin.
This exchanger is one example of an alternative mechanism of P-gp leading to MDR.
Also, testing of mrp1/abcc1 and bcrp/abcg2 (with mdr1, these compose the major drug
efflux pumps expressed in human cancers), other types of exchangers or other secondary
or primary transporters could elucidate the mechanism by which goldenseal exerts its
effect [13]. The use of low-density DNA microarray to analyze these sets of genes to see
the effects of GSL 2:2 on their expression would provide a method to examine a large
pool of genes at once [108].
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Lin and colleagues reported that berberine was able to induce the expression and
function of P-gp in six cancer cell lines (2 gastric, 2 oral, and 2 colon) [109]. They also
determined that berberine can upregulate P-gp expression in hepatoma cells [110]. As a
nice supplement to this study, pure berberine could be assayed for its effect on P-gp
expression and function in the CCD-18Co, HT-29 and HT-29/Dox colon cell lines.

Additionally, berberine itself has the ability to halt the cell cycle (through dual
topoisomerase I and II poisoning activity and intercalation into the minor groove of
DNA) and it can induce apoptosis in many carcinoma lines in vitro [107]. In oral
squamous cell carcinoma berberine inhibits cellular DNA synthesis in addition to
inhibiting cell growth in G0/G1, correlating with activation of caspase-3, induction of
reactive oxygen species, production of Ca++, and disruption in mitochondrial membrane
potential, which equates to an endoplasmic reticulum stress response [111]. Testing
goldenseal on these cellular aspects may be a good starting point to assessing its
enhanced effects over that of pure berberine.

Characterization of the specific absorption, distribution, metabolism (activation,
detoxification) and excretion of GSL 2:2 in the body would prove very useful as well. In
vivo follow-up studies testing the effects of goldenseal to prevent cellular metastases
would be a good extension of this study.
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